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Zusammenfassung
Die Fehlregulation zentraler Signalwege, die zu einem gesteigerten U¨berleben,
gesteigerter Proliferation oder reduzierter Apoptose der Zelle fu¨hren, wurde fu¨r fast
alle malignen ha¨matologischen Erkrankungen beschrieben. Einer der bekanntesten
Signalwege, der das U¨berleben und die Proliferation in ha¨matopoeitischen Zelle reg-
uliert, ist der NF-B-Signalweg. Insbesondere wurden Mutationen und Deletionen
in den Schlu¨sselkomponenten dieses Signalweges in di↵us großzelligen B-Zell Lym-
phomen vom aktivierten Typ gefunden (ABC-DLBCL). Das Moleku¨l Receptor Ac-
tivator of NF-B (RANK), welches in ca. 8% der Tumoren von ABC-DLBCL Pa-
tienten mutiert ist, fu¨hrt im physiologischen Kontext nach Bindung seines Liganden
RANKL zu einer Aktivierung der NF-B, MAPK und PI3K Signalwege. Eine umfan-
greiche Literaturrechere die ergab, dass eine RANK Fehlregulation auch in malignen
B-Zell Erkrankungen, wie der chronisch lymphatischen Leuka¨mie (CLL), dem mul-
tiplen Myelom und dem Hodgkin Lymphom beschrieben ist. Dennoch sind die in
vivo Konsequenzen fehlgesteuerter RANK Signalleitungen in B-Zellen weitgehend
unklar. Deshalb ist die hier durchgefu¨hrte Studie darauf ausgerichtet durch kondi-
tionale Mutagenese ein neues Mausmodell zu entwickeln, bei welchem die Expression
der lymphomassoziierten RANK(A756G) selectiv in vivo induziert werden kann, um
die E↵ekte von mutierter RANK(A756G) Expression auf B-Zellen zu analysieren.
Die Analyse dieser Tiere ergab, dass die RANK(A756G) Expression ab dem
pre-B-Zell Stadium in Ma¨usen eine lymphoproliferative Autoimmunerkrangung mit
Systemic Lupus Erythematosus (SLE)-a¨hnlichen Eigenschaften verursacht. Hierzu
geho¨ren eine spontane Produktion von antinuklea¨ren Antiko¨rpern (ANA), eine mas-
sive B1-B-Zell Expansion und eine Immunkomplex-Akkumulation mit Nephritis
bishin zum Nierenversagen. Eine detailerte Analyse der RANK(A756G)- exprim-
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ierenden B-Zellen ergab, dass diese im Vergleich zu wildtyp B-Zellen besser u¨berlebten
und durch die Aktivierung der ERK, JNK und PI3K Signalwege versta¨rkt prolif-
erierten. Durch diese induzierte RANK Aktivierung werden Gene wie zum Beispiel
Bcl-2 und Cyclin D1 induziert, die fu¨r das U¨berleben und die Zellteilung wichtig
sind, und apoptotische Gene, wie zum Beispiel APC und PTEN herabreguliert.
Dies wurde jedoch ausschließlich nach RANKL Bindung beobachtet. Stromazellen
aus dem Knochenmark und aktivierte CD4+ T Zellen exprimieren RANKL und
verursachen somit eine starke Aktivierung und Proliferation der RANK(A756G)-
transgenen B-Zellen. Im Einklang mit dieser Erkenntnis wurde beobachtet, dass
es im Knochenmark von RANK(A756G)CD19-Cre Ma¨usen eine substantielle Ex-
pansion stark aktivierter unreifer B- Zellen gab. Als Zusammenfassung wird fol-
gendes Modell vorgeschlagen: Die RANK(A756G)-RANKL Interaktion treibt eine
vorzeitige Aktivierung von B-Zellen im Knochenmark die dazu fu¨hrt, dass sich ein
autoreaktives B-Zell-Repertoire anreichert. Durch den U¨berlebens- und Prolifera-
tionsvorteil der Zellen, akkumulieren diese und werden zusa¨tzlich durch CD4+ T
Zellen aktiviert, was letztendlich zu einer Autoimmunerkrankung bei Ma¨usen fu¨hrt.
Die vorliegende Studie zeigt, dass eine deregulierte und aberrant aktivierte RANK
Signalwirkung ausreichend ist, um die B-Zell-Homeostase in vivo zu durchbrechen
und Autoimmunita¨t zu induzieren. Basierend auf dem bekannten pathophysiolo-
gischen Zusammenhang zwischen Autoimmunita¨t und Lymphomentstehung, liefern
diese Daten und das neuartige Mausmodel auch eine Grundlage fu¨r das Versta¨ndnis
der RANK(A756G)-Mutation bei humanen Lymophomen.
Abstract
Dysregulation of several cellular signaling pathways that lead to enhanced cell
survival, proliferation, and reduced apoptosis has been described for all hematopoi-
etic malignancies. One of the most prominent pathways that regulates cell survival
and proliferation is NF-B. Recently, a set of mutations leading to deregulation and
overactivation of the NF-B pathway have been detected in human Activated B
cell-like Di↵use Large B cell lymphoma (ABC DLBCL). Among these mutations, a
mutation in the Receptor Activator of NF-B (RANK) gene, the K240E mutation,
which leads to an amino acid change from Lysine to Glutamic acid at position 240,
was found in 8% of ABC-DLBCL tumors. RANK is a transmembrane receptor that
exerts after physiological binding to its ligand RANKL prosurvival, proliferative and
anti-apoptotic e↵ects on target cells through the activation of NF-B, MAP kinase
and PI3K pathways. Deregulation of RANK-RANKL signaling, disruption of the
balance between RANK/RANKL concentrations and overexpression of RANK have
also previously been described for cases of Hodgkin’s lymphoma, Multiple myeloma
and B cell chronic lymphocytic leukemia (B-CLL). However, the in vivo conse-
quences of the deregulation in RANK signaling are not well understood. Therefore,
the study at hand generated and analyzed a novel mouse model to determine the
e↵ects of B cell restricted enforced RANK(A756G) expression in B cells, through
conditional mutagenesis.
We observed that the enforced RANK(A756G) expression starting as early as
in the pre-B cell stage drives an autoimmune disease with Systemic Lupus Erythe-
matosus (SLE)-like symptoms, such as presence of anti-nuclear antibodies, B1-B cell
expansion and deteriorating renal function with immunoglobulin complex accumu-
lation in kidneys and kidney failure. The RANK(A756G) expressing B cells showed
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enhanced survival and proliferation through the activation of ERK, JNK and PI3K
pathways. Activation of these pathways led to increased expression of genes impor-
tant for survival and proliferation, such as Bcl-2 and Cyclin D1, as well as decreased
expression of pro- apoptotic genes such as APC and PTEN. The pro-survival and
proliferative e↵ect of RANK(A756G) expression was shown to be ligand dependent.
Stromal cells in the bone marrow and activated CD4+ T cells express RANKL and
this led to a strong activation of transgenic B cells ex vivo. In line with this finding,
we observed in the bone marrow of RANK(A756G)CD19-Cre mice a massive accu-
mulation with immature B cells that were highly activated. Together, based on these
findings, we propose the following model: Enforced RANK-RANKL binding drives
premature activation of B cells in the bone marrow, leading to an autoreactive B cell
repertoire with enhanced survival and proliferative advantage, that over time accu-
mulate and drive an autoimmune disease in mice. Thus, the study at hand shows
that selectively deregulated and aberrantly activated RANK signaling is su cient
to disrupt B cell homeostasis and trigger spontaneous autoimmunity. Based on the
known pathophysiological link between autoimmunity and lymphomagenesis, these
results and our new genetic mouse model provide the basis for the understanding of
RANK(A756G) function during human lymphomagenesis.
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Chapter 1
Introduction
1.1 The Immune System and Adaptive Immunity
1.1.1 General Features of the Immune System
The immune system has evolved to protect the host from invading pathogens.
It is equipped with various tools that serve this purpose and can be roughly di-
vided into two branches, based on their mechanisms of action. The first branch,
the innate immune system provides a rapid response to an invading organism. This
response usually lacks specificity and memory, is mainly driven by di↵erent cells of
the myeloid lineage, such as the macrophages, neutrophils and dendritic cells, and is
orchestrated through an array of cytokines and chemokines [1]. Danger signals are
detected via pattern recognition receptors (PRRs) that recognize certain common
motifs on the surface of pathogens, namely, pathogen-associated-molecular-patterns
(PAMPs) [1, 2]. Detected pathogens are phagocytosed and thus eliminated. Innate
immunity initiates inflammatory response and orchestrates an adaptive immune re-
sponse through the presentation of the processed antigens to the cells of the adaptive
immune system [3]. Adaptive immunity, on the other hand, takes longer time to re-
spond, is strictly antigen specific, is capable of developing memory for a previously
encountered antigen and is driven by the cells of the lymphoid lineage, namely the
B cells and T cells. It is the precise crosstalk between these two branches of the
immune system that makes it so e cient in detecting and eliminating the diverse
1
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repertoire of pathogens the host encounters during the course of its lifetime [1, 4].
The major players in adaptive immunity are the B and T cells. One trait the two
cell types have in common is the presence of an antigen receptor on the cell surface
[5]. The antigen receptor is highly specific to a certain antigen and is generated by
somatic gene rearrangements during the early development of a B or T cell. B and T
cells arise from common lymphoid progenitors in the bone marrow. T cell precursors
then migrate to the thymus where they continue their development, whereas B cells
remain in the bone marrow. Once lymphocytes acquire a correctly rearranged anti-
gen receptor in the primary lymphoid tissues they are developing in, they migrate
into secondary lymphoid tissues, namely the spleen and lymph nodes, where they
encounter their respective antigen, carried in via blood or the lymphatic system.
B cells recognize intact antigens, whereas T cells can only recognize antigens that
have been phagocytosed, processed as peptides and docked on major histocompat-
ibility complex molecules on the surface of antigen presenting cells (APCs). Once
the antigen is recognized, T cells provide cell-mediated immunity, through which the
infected cell can be eliminated by cytotoxic T cells that are positive for the surface
marker cluster of di↵erentiation 8 (CD8). Alternatively, CD4 positive T cells can
induce cytokine secretion and help orchestrate a cellular response for the antigen
to be eliminated. B cells on the other hand, provide humoral response against the
antigen. Upon recognition of the antigen and depending on the cytokine help from
the environment, B cells secrete a variety of antibodies that aid the elimination of
antigen [1, 6, 7, 8].
B cells play a primary role in humoral immunity, can present extracellular patho-
gens and toxins to T cells and are therefore indispensable for a fully functioning
adaptive immune system. So far, two main subtypes of B cells have been discovered,
namely, the B1 B cells and the B2 B cells, with distinct developmental stages and
functions [9]. The next section will focus on the development of B2, or “conventional”
B lymphocytes.
1.1.2 B2 B Lymphocyte Development
B2 B cells develop in the fetal liver and adult bone marrow in humans, as in
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all mammals, from multipotent, self-renewing hematopoietic stem cells (HSCs),
throughout the host’s life [10]. Early development of B2 B cells depends on the
interaction of B cell precursors with the bone marrow stroma and is strictly coordi-
nated through temporal regulation of cytokine and chemokine secretion, as well as
transcription factor expression. The HSCs in the bone marrow initially di↵erentiate
into multipotent progenitor cells (MPPs). MPPs are capable of di↵erentiating into
either myeloid or lymphoid cells, but are no longer capable of self-renewal. MPPs
express the FLT3 receptor on their surface, and through their interaction with the
FLT3 ligand on the bone marrow stromal cells, can further di↵erentiate into common
lymphoid progenitors (CLP). From then on, the CLPs commit to a B cell lineage
through the interaction of the interleukin-7 (IL-7) receptors on their surface with
the IL-7 secreted from the bone marrow stromal cells, becoming pro-B cells. B cell
specific transcription factors such as E2A and early B-cell factor (EBF) are also
expressed during this developmental stage. Murine pro-B cells depend on IL-7 for
survival, whereas the human pro B cells do not. The stages of di↵erentiation from a
pro-B cell to a pre-B cell and then an immature B cell is marked by the production
and surface expression of an antigen receptor, or the B cell receptor (BCR) [1, 11].
The BCR consists of two chains, namely, the heavy chain (H-chain) and the
light chain (L-chain), which are produced by gene rearrangement through somatic
recombination. In humans, as well as in mice, there are several variable (V), diversity
(D), joining (J) and constant (C) gene segments in the genome, for the formation of
a heavy chain. The gene rearrangement process is initiated by the upregulation of
recombination-activating genes RAG-1 and RAG-2 and the activation of the VDJ
recombinase complex. The VDJ recombinase complex brings about the cutting and
joining of the D-J region first, and then that of the V region, to form a correctly
rearranged VDJ region. Once the H-chain is rearranged, a surrogate light chain is
expressed to form the pre-B cell receptor during the pre-B cell stage. Successful
signaling from the pre-B cell receptor halts any further recombination events in the
heavy chain locus (allelic exclusion), and leads to cell survival and proliferation.
Light chain rearrangement from V and J regions in the genome and the binding to
the constant region, which mediates the e↵ector functions of an antibody, leads to
the production of a successfully rearranged antigen receptor, surface immunoglobulin
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M (IgM), and the progress into the immature B cell stage. The maturation of a B
cell is marked by the double expression of IgM and IgD on its surface [1, 12].
The random joining of V, D and J segments from a selection of available gene
segment sequences provides combinatorial diversity for the antigen receptor. The in-
accurate splicing of the segments can result in frameshifts, and hence in the produc-
tion of a di↵erent protein, providing junctional diversity to the receptor repertoire.
During the ligation of the spliced segments, the enzyme deoxyribonucleotidyltrans-
ferase (TdT), which is a part of the VDJ recombinase complex, can add random
untemplated nucleotides, contributing further to diversity. All these mechanisms of
diversification ensure that the host is supplied with a large enough antigen receptor
repertoire that will su ce for the entirety of the host’s life, with the limited available
space in the genome [13, 14].
Once the B2 B cells reach the immature stage, they egress from the bone marrow
and move to peripheral lymphoid tissues via the circulation. Upon reaching the
spleen, they acquire di↵erent functions, depending on their location. B cells that
reside in the marginal zone of the splenic pulp (MZ B cells) serve as a first line
of defense against blood-borne pathogens and show primarily T cell independent
humoral responses. MZ B cells do not recirculate and remain in the spleen. Once
the MZ B cells encounter their respective antigens, they develop into plasma cells
without the need of T cell help, and secrete mainly IgM antibodies that have low
antigen a nity [15, 16].
Most mature naive B2 B cells migrate to the B cell follicles in the spleen and
lymph nodes and are called follicular B cells (FO B cells). Once they are activated
by their respective antigen, they phagocytoze, process and start presenting its epi-
topes on their surface on MHC II molecules, they move to the boundary between
the follicle and T cell area, where they can get T cell help from CD4+ T cells that
can detect the same antigen. This interacton is mainly mediated by MHCII presen-
tation of the antigen by B cells, costimulation of the B cell through CD40 receptor
(on B cells)- CD40 ligand (on T cells) binding and secretion of cytokines such as
IL-21. Once all these signals are received by the B cell, it undergoes germinal center
(GC) reaction, driven mainly by the transcription factor Bcl-6 and starts prolifer-
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ating (clonal expansion) [17, 18]. One of the most important genes upregulated for
a GC reaction is activation-induced deaminase (AID). AID is expressed specifically
in activated B cells and deaminates cytidine residues in immunoglobulin V regions,
leaving uridine residues, whose presence in DNA triggers DNA repair response. Dur-
ing DNA repair new mutations are introduced to the V region, which leads to the
expression of altered antigen receptors. B cells which have a receptor with stronger
a nity towards the antigen bind the available antigen, get further T cell help and
survive in the GC, whereas the B cells with lower a nity receptors undergo apop-
tosis. This process through which a BCR repertoire with a higher a nity towards
a specific antigen is generated, is called a nity maturation through somatic hyper-
mutation (SHM) [1, 19, 20]. A second process that occurs through the activity of
AID is class-switch recombination (CSR). When AID deaminates cytidine residues
in the “switch regions”, the induced double stranded breaks are repaired and the C
region of the µ chain is replaced by other Ig classes.A nity maturation and CSR
results in further diversification of the B cell repertoire [1].
Proliferating B2 B cells with a high a nity BCR become plasma cells and start
producing somatically hypermutated and class switched antibodies, a developmental
stage initiated by the expression of the transcription factor B-lymphocyte induced
maturation protein-1 (Blimp-1) [21]. Short lived plasma cells can survive around 2-3
weeks after antigen encounter, whereas long lived plasma cells migrate to the bone
marrow where they can reside for the life of the host [22]. Alternatively, B2 B cells
can become memory cells after the GC reaction and contribute to immunological
memory [21, 22].
1.1.3 B1 B Lymphocyte Development
Murine B1 B cells are derived from the fetal liver and are sustained in the
periphery by self-renewal, rather than being continuously produced de novo in the
bone marrow, in contrast to B2 B cells. They are the main cell population in the
peritoneal and pleural cavities, and are found rarely in the spleen or lymph nodes
[23]. There is ongoing debate about whether B1 and B2 B cells are derived from a
common progenitor and the divergence is driven by antigen-dependent selection (the
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selection model), or instead arise from di↵erent precursors of separate lineages (the
lineage hypothesis) [24]. Considerable evidence has gathered in favor of the lineage
hypothesis. B1 B cells are further divided as B1a (CD5+) and B1b (CD5-) cells [25].
B1 B cells are generated mainly before birth, starting as early as day 8.5 of
mouse embryonic development, continuing into the first weeks after birth, and are
sustained through self-renewal from then on, with a slow turn-over rate [26]. B1
cell development strongly depends on BCR ligation and nuclear factor-kappa B
(NF-B) signaling. Studies have shown that the H-chain V segments used by B1
B cells are more restricted than that of B2 B cells, meaning that the B1 B cell
repertoire is less diverse [27]. B1 B cells secrete polyreactive low-a nity antibodies
against self-antigens, antigens expressed by apoptotic cells and several PAMPs [28].
The general polreactivity of B1 B cells ensures sustained BCR signaling and allows
them to escape negative selection during development [29]. Self-reactivity of B1 B
cells makes them the major supplier of “natural antibodies” of IgM class, which are
present even in the absence of microorganisms, as was shown for germ-free mice [30].
B1 B cells are capable of class switching into any antibody in vitro, whereas in vivo,
they preferentially switch to IgA [31].
B1 B cells can produce high levels of polyreactive IgM antibody at infection sites,
or can migrate from the peritoneal cavity to the spleen or mucosal tissue in response
to intraperitoneal or blood-borne pathogens and secrete IgM or IgA, respectively.
There is also evidence that B1b cells contribute to immunological memory formation
after an infection and a memory B cell population that resemble B1 B cells have
been detected in the peritoneal cavity of mice [31, 32].
A population of CD5+ B cells has also been shown to exist in adult humans,
although they do not reside in the peritoneal cavity as a distinct cell population.
Although B1 B cells have various roles in tissue maintenance and pathogen elimi-
nation, their self-reactivity makes them prone to becoming pathological and B1 B
cells have been implicated in autoimmune diseases [33]. Surface marker proteins of
di↵erent subtypes of conventional B cells in mice throughout their developmental
stages are shown below in Table 1.1 [34].
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B cell subpopu-
lation
Positive Surface Markers
Negative Surface
Markers
pre-pro-B
CD43, CD93, CXCR4, B220,
Flt3, IL7R
CD19, ckitlow, CD24low,
IgM
pro-B CD19, CD43, CD24, B220, IL7R BP1, Flt3, ckitlow, IgM
pre-B
CD19, CD25var, CD24, B220,
BP1, Siglec-G, IL7R
CD43low, ckit, IgM
Immature B CD19, CD24, CD93, B220, IgM CD43, CD23, IgD
Transitional B
CD19, CD24, CD93, CD21var,
CD23var, B220, IgMhigh
IgDlow
Marginal zone
CD1d, CD9, CD21high, CD22high,
CD35high, B220, IgM
CD93, CD23, IgDlow
Regulatory
CD1dhigh, IgMhigh, CD5, CD19,
CD24, TIM
CD62L, CD93var, IgDvar
Follicular
CD19, CD22, CD23, CD38, B220,
IgD
CD1dlow, CD21/35low,
CD93, IgMlow
Activated B
CD27, CD69, CD80, B220, Flt3,
MHCIIhigh, IgM, IgD
CD138, CXCR4
Germinal Center B
CD19, CD37, CD20, GL7,
Siglec2, IgM/G/A/E
CD93, CD38low, IgDvar
Plasmablast
CD19, CD138, CXCR4, MHCII,
IgM/G/A/E+
B220low, Flt3
Plasma cell (long
lived)
CD138, CXCR4high
CD19, CD38low,B220low,
MHCII, Ig
Plasma cell (short
lived)
CD138, CD93, CXCR4high
CD19,CD38low, B220low,
MHCIIlow, Ig
Memory B IgM/G/A/E+, B220
CD38var,CD62Lvar,
CD80var, CD95low, IgD–
Table 1.1: Expression of surface markers on conventional mouse B cells during their
development and di↵erentiation.
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1.1.4 B Cell Receptor Signaling and Antibody Secretion
The B cell receptor essentially consists of a surface immunoglobulin accompanied
by signaling proteins Ig↵ and Ig  that contain cytosolic immunoreceptor tyrosine-
based activation motifs (ITAMs) [1]. BCR crosslinking activates the receptor asso-
ciated Src-family protein tyrosine kinases (Blk, Fyn or Lyn) which in turn phos-
phorylate the ITAMs of Ig↵ and Ig . Phosphorylated ITAMs bind and activate the
spleen tyrosine kinase (Syk), which initates a signaling cascade through Bruton’s ty-
rosine kinase (BTK) that results in the activation of phospholipase C- 2 (PLC- ),
clevage of membrane bound phospholipid PIP2, initiation of Ca2+ influx, activation
of mitogen-activated protein kinases (MAPKs) and the activation of transcription
factor NF-B via the Carma1/Malt1/Bcl-10 (CBM) complex, along with several
other transcription factors such as AP-1 and NFAT. These transcription factors
induce transcription of specific genes, leading to cell proliferation, di↵erentiation
and cytokine signaling. While receptors with an ITAM motif positively regulate sig-
naling cascades, receptors with an immunoreceptor tyrosine-based inhibitory motifs
(ITIMs) inhibit signaling pathways. Receptors with an ITIM motif recruit inhibitory
phosphatases SHP and SHIP that remove the phosphate groups added by the tyro-
sine kinases. One example of an ITIM-containing inhibitory receptor is programmed
death 1 (PD-1), which is induced transiently on activated B, T and myeloid cells
to keep the signaling pathways in check. A detailed scheme of the BCR signaling
cascade can be seen in Figure 1.1 [1, 35, 36].
Antigen dependent signaling from the BCR is enhanced when the BCR co-
receptor is also bound by its respective ligand. The BCR co-receptor consists of
CD19, CD21 and CD81, from which CD21 binds fragments of complement on the
pathogen. This induces phosphorylation of the cytosolic tail of CD19, enhancing
the signal coming from the BCR [37]. Upon antigen stimulation, B cells also up-
regulate surface molecules CD80 and CD86, along with MHCII, which provide a
costimulatory signal for T cells during B-T cell interaction [1, 38].
As mentioned above, antigen recognition by the BCR along with T cell help
leads to antibody class switching. Di↵erent cytokines induce switching to di↵erent
classes of antibodies, namely, IgG, IgE and IgA. IL-4 induces IgG1 and IgE switch,
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Figure 1.1: B cell receptor signaling cascade. Crosslinking of the BCR fol-
lowing receptor-specific antigen binding activates a signaling cascade through which
receptor associated Src-family protein kinases phosphorylate the ITAMs of Ig↵ and
Ig , which phosphorylate and activate Syk and BTK, leading to the activation of
PLC- 2. PLC- 2 then cleaves the membrane bound PIP2 into IP3 and DAG. IP3
and DAG conduct the Ca2+ influx regulated activation of PKC , which leads to
the activation of the NF-B pathway through the assembly of the CBM complex.
DAG also mediates the activation of MAPKs and the transcription factor AP-1
through small G proteins Ras and Raf. IP3 regulated Ca2+ influx also leads to the
activation of the transcription factor NFAT. NFAT, AP-1 and NF-B transcription
factors in turn, induce expression of genes related to cell survival, proliferation and
di↵erentiation.
whereas interferon gamma (IFN- ) induces IgG3 switch [39, 40]. Antibody classes
are determined by the C region of IgH locus and they operate in distinct locations
with distinct e↵ector functions. IgA acts in the gut lumen as dimers, IgG and IgM are
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prevalent in the blood, and IgE is mostly associated with mast cells below epithelial
surfaces. IgG and IgA are e↵ective in neutralization and opsonization of the antigen,
while IgM is essential in activating the complement system and IgE is important for
the sensitization of mast cells [1].
B cells are an essential part of the adaptive immune system, both due to their
antigen presenting role and to their primary role in humoral immunity. B cell devel-
opment and di↵erentiation is intricate, temporally and spatially strict and involves
many genetic recombination and mutation events. It is therefore necessary that de-
velopmental stages are strictly regulated with several checkpoints. Failure of these
checkpoints results in severe pathology, in the form of lymphoid malignancies or
autoimmunity. The next section focuses on B cell checkpoints and their breakdown
during pathology.
1.2 B Cell Checkpoints and Pathology
1.2.1 Checkpoints in B Lymphocyte Development
One of the vital features of B cell e↵ector mechanisms is the ability to discrim-
inate self from non-self. During several stages of B cell development, the newly
generated antigen receptors are checked for autoreactivity. The initial checkpoint is
in the bone marrow, after the immature B cell stage, and is known as the central
tolerance [41]. Immature B cells, which have no strong reactivity to self antigens
and express surface IgM are allowed to mature and leave the bone marrow. The
cells that bind self antigens that are ubiquitously expressed surface molecules un-
dergo apoptosis (clonal deletion) or receptor editing, a process through which the
receptor can be modified to become non-autoreactive [1, 42]. Cells that recognize
soluble self molecules that are more weakly cross-linked, become anergic, a state
of permanent unresponsiveness, and move to the periphery, where their clones are
quickly outgrown by potent, non-self reactive B cells via their survival and prolifer-
ative advantage [42]. Some self-reactive B cells might escape this checkpoint, if their
antigen is not available to them or they have a low a nity for self antigens, and
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move to the periphery along with the non-autoreactive immature B cells, and are
allowed to mature [1].
In case autoreactive B cells escape the central tolerance checkpoint, they may
be inactivated in the periphery. Here the innate immune system comes into play. In
the presence of an external antigen, the innate immune system provides signals that
activate adaptive immunity to respond to the infection. If an antigen is recognized
by B cells in the absence of infection, and hence in the absence of pro-inflammatory
cytokines and co-stimulatory surface molecules, this leads to an inactivating negative
signal and to the elimination of the autoreactive B cell. This second checkpoint
mechanism is known as peripheral tolerance [43].
1.2.2 Autoreactive B Lymphocytes and Autoimmune Dis-
orders
Some B cells which have low a nity for self antigens manage to escape the check-
points, simply due to the fact that their respective antigen was not presented, or
due to a breakdown in the tolerance mechanisms and an alteration in BCR signaling
thresholds [44]. Another mechanism through which B cells can become autoreactive
is somatic hypermutation in the germinal centers. Some B cells might acquire mu-
tations that increase their a nity for self-antigens and fail to be eliminated [45].
These autoreactive B cells might occasionally detect their antigens in the presence
of costimulation, for instance during an infection.
One such example is the activation of B cells specific for chromatin components
in systemic lupus erythematosus (SLE). SLE is a systemic autoimmune disease,
characterized by extensive secretion of anti-nuclear antibodies (ANAs), such as au-
toantiboies against DNA, chromatin proteins or ribonucleoproteins, and aggregation
of immune deposits in organs, mostly kidneys, leading to lupus nephritis and kidney
failure [46]. In an event of extensive apoptosis and reduced clearance of apoptotic
cells, possibly as a result of an infection, B cells that recognize nuclear proteins might
get the opportunity to bind to and internalize their antigens. DNA from apoptotic
cells are enriched in unmethylated CpG residues, which are rare in humans compared
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to microbes and thus serve as PAMPs for Toll-like receptor (TLR)9, an intracellular
innate immunity receptor. TLR9 might bind its PAMP in endosomes and send a
co-stimulatory signal, leading to the activation and expansion of an autoreactive
B cell clone. These B cells can, in addition to secreting auto-reactive antibodies,
present the antigen to auto-reactive T cells and activate them [1].
Another instance where autoreactive B cells can be activated is when their pre-
viously nonimmunogenic self antigen adopts an immunogenic form. For example,
some autoreactive B cells that are specific for IgG are not activated under steady
state conditions, despite the abundance of IgG in blood, because IgG is monomeric
and does not cross-link the BCR. However, during a severe infection, IgG molecules
dimerize and can be detected by autoreactive B cells, leading to the production of
anti-IgG antibodies. If the immune complexes are cleared rapidly after an infection,
this does not constitute a problem for the host. However, long-lasting exposure of the
autoreative B cells to their antigen leads to sustained production of these anti-IgG
antibodies, also known as rheumatoid factor, since it is commonly seen in rheuma-
toid arthritis [1]. Rheumatoid arthritis is an autoimmune disease characterized by
inflammation of joints. It is mediated by both CD4+ T cells and B cells, which
upon T cell help generate arthritogenic antibodies in a pro-inflammatory environ-
ment, leading to tissue destruction.
Autoimmune disorders are defined by Davidson and Diamond as “clinical syn-
dromes mediated by the abnormal activation of B cells or T cells, or both, in the
absence of ongoing infection or other discernible cause” [47]. They can present ei-
ther as a systemic disease or an organ-specific disease [48]. Autoimmune disorders
can arise from a general defect in the selection or death of B or T cells, or due to
abnormal response to one particular self-antigen. Genetic factors are crucial in de-
termining the susceptibility to autoimmune diseases. Defects in the Fas ligand or its
receptor, which mediate apoptosis in activated immune cells, mutations in the MHC
alleles, or genetic alterations in genes encoding cytokines or antigen coreceptors are
implicated in the development of autoimmune disorders, mostly working in con-
cert with each other [49]. Vulnerability of the target organ to autoimmune-induced
damage is also shown to be determined genetically. An autoimmune disorder can
be initiated by environmental factors, infection, as mentioned above, non-infectious
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agents such as drugs that alter the immune phenotype, or loss of regulatory cells
that moderate immune response. As the disease progresses, it is possible that the
autoantigens targeted by T and B cells increase due to the pro-inflammatory en-
vironment and constant antigen presentation, which makes it clinically di cult to
determine the initiating antigen [50].
The common objective of therapeutic approaches to autoimmune diseases is to
down-modulate the immune system activity. One strategy to achieve this is to block
molecules such as TNF-↵, interleukin receptors or CD4 [51]. In SLE, CD40 ligand
blockade was shown to be highly e↵ective in murine mouse models, but not in
humans due to side e↵ects [52, 53]. The first biological drug approved by the FDA for
treatment of SLE is belimumab, which is a monoclonal antibody that blocks B-cell
activating factor (BAFF), a cytokine that regulates B cell survival and di↵erentiation
[54]. Further knowledge on the involvement of B and T cells in the progression of
autoimmune disorders, along with genetic factors and initiating antigens is necessary
to develop e↵ective courses of treatment.
1.2.3 B Lymphocyte Development and Lymphoid Malig-
nancies
B cell development and di↵erentiation contains several steps where the genomic
integrity is compromised or cells expand rapidly. When these processes, inherently
risky and error prone, go awry, the consequences for the organism can be severe,
and lead to malignancies, namely, leukemias and lymphomas [55]. One such pro-
cess is the V(D)J recombination. During the recombination events that lead to the
generation of Ig heavy and light chains, double stranded breaks that are induced
by RAG enzymes can be repaired in an aberrant fashion, leading to chromosomal
translocation. Chromosomal translocations typically lead to the replacement of the
regulatory elements of a gene by a part of another gene, resulting in dysregulated
gene expression. Later in the life of a B cell, i.e. during GC reaction, SHM and CSR,
which also require induction of DNA breaks, chromosomal translocations may arise.
Dysregulated expression of several genes such as Bcl-2, cyclin D1, Bcl-6, that are
important for cell proliferation and apoptosis leads to malignancies like follicular
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lymphoma, mantle-cell lymphoma or Burkitt lymphoma, respectively [56, 57, 58].
Lymphomas are generally named after the normal B cell counterpart of malig-
nant B cells. In mature B cell lymphomas, the malignant cells are usually arrested
at a certain B cell developmental stage [55]. In Hodgkin’s lymphoma for instance,
the malignant Hodgkin and Reed-Sternberg (HRS) cells originate from GC B cells
[59]. Di↵use large B-cell lymphoma (DLBCL), which is the most common non-
Hodgkin’s lymphoma in adulthood (30-40% of the cases) have two subtypes based
on their gene expression profiling [60]. GC B-cell-like DLBCLs (GCB DLBCLs) have
a gene-expression profile that resembles a B cell undergoing GC reaction (such as
high expression of GC B cell signature gene Bcl-6), and thus are thought to origi-
nate from GC B cells, whereas activated B-cell-like DLBCLs (ABC DLBCLs) have
a gene expression profile that resembles activated B cells, with a pronounced ex-
pression of NF-B target genes such as cyclin D2 and Bcl-2. ABC DLBCLs are
therefore postulated to arise from pre-plasma cells, and are arrested at this devel-
opmental stage [61]. Mutations of several genes that lead to dysregulation of the
NF-B pathway is a hallmark of ABC DLBCLs. In 30% of ABC DLBCL cases, the
activity of A20, which is a negative regulator of the NF-B pathway is impaired by
inactivating mutations or deletions. Positive regulators such as CARD11, TRAF2,
TRAF5 and receptor activator of NF-B (RANK) are also a↵ected by activating
somatic mutations that enhance their ability to activate the NF-B pathway. The
collective inhibition of NF-B inactivating genes with the activation of NF-B ac-
tivating genes lead to constitutive activation of the NF-B pathway and thus to
uncontrolled cell proliferation and reduced cell death, promoting lymphomagenesis
[62].
Since di↵erent subtypes of lymphoma originate from B cells at di↵erent develop-
mental stages, with distinct gene expression profiles, the strategies for treating each
subtype along with the response to treatment from each subtype are also di↵erent.
ABC DLBCLs for instance, have a worse prognosis compared to GCB DLBCLs [61].
The elucidation of gene expression profiles may help develop di↵erential treatments
for these two subtypes of DLBCLs. ABC DLBCL cases that do not respond to
conventional therapies can additionally be treated with selective NF-B inhibitors,
such as, bortezomib, which is a proteasome inhibitor that prevents degradation of
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inhibitors of the NF-B pathway [63]. However, 17% of ABC DLBCL patients are
refractory to bortezomib and further understanding of the NF-B mechanism may
unravel further treatment options [64].
As mentioned above, one of the genes that carry somatic mutations in ABC
DLBCL patients is RANK. The next section focuses on the function of RANK and
its putative role in development of pathology.
1.3 Receptor Activator of NF-B: Function and
Pathology
1.3.1 Characteristics and Function of Receptor Activator of
NF-B Signaling
RANK (also designated TNFRSF11A), is a homo-trimerizing transmembrane re-
ceptor that belongs to the tumor necrosis factor (TNF) superfamily. RANK trimer-
izes after binding its ligand, the RANK ligand (RANKL, also designated TNFSF11)
which can be found both in membrane-bound and soluble form. The cleavage of sol-
uble RANKL from the membrane bound form is mediated by a metalloprotease,
TNF-a convertase (TACE). Murine RANKL shares 83% homology with human
RANKL. RANK is not the only receptor for RANKL that is so far discovered.
Osteoprotegerin (OPG, also designated as TNFRSF11B), a soluble protein distinct
from RANK, binds and neutralizes RANKL and balances RANK signaling by act-
ing as a decoy receptor. Upon binding its ligand and trimerizing, RANK, which
lacks kinase activity itself, recruits TRAFs 2,3,5 and 6 to its cytoplasmic domain
to distinct binding motifs, which in turn activate MAPKs and the canonical and
non-canonical NF-B pathways. RANK signaling is also essential in the induction
of transcription factors c-fos and NFATc1/NFAT2. A detailed scheme of the RANK
signaling pathway is shown in Figure 1.2 [65, 66, 67].
NF-B is a transcription factor complex that comprises di↵erent dimeric subunits
which slightly di↵er in function. The first family of NF-B proteins is the REL family,
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Figure 1.2: Receptor Activator of NF-B signaling cascade. Upon binding
its ligand, RANKL, RANK recruits TRAFs which relay the signal downstream, and
induce the activation of JNK, ERK and p38 MAPKs, the PI3K pathway and the
alternative and canonical NF-B pathways, leading to cell survival, proliferation
and osteoclastogenesis. RANKL can be found in membrane-bound or soluble form,
cleaved by metalloproteases. OPG, a soluble decoy receptor for RANKL distinct from
RANK is essential in balancing the RANK-RANKL signaling axis and abrogating
signaling by binding excess RANKL.
with members RELA (also known as p65), RELB and c-REL. The second family
comprises the proteins NF-B1 (also known as p105) and NF-B2 (also known as
p100), which are precursors that are processed to form the mature proteins p50 and
p52, respectively. Combination of these proteins in dimers gives rise to two slightly
di↵erent pathways, namely the canonical and non-canonical pathway. The canonical
pathway utilizes RELA, c-REL and p50 dimers, which are normally sequestered
in the cytoplasm by inhibitor of B proteins (IB) in the steady state. Once a
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signaling pathway is activated, i.e. after by the binding of RANKL to RANK, the
TRAFs that are recruited to the cytoplasmic domain, bind and activate the IB
kinase complex (IKK), which then phosphroylates IB by its   subunit, and marks
it for ubiquitinylation. The non-canonical pathway on the other hand, utilizes the
RELB-p52 dimers and is regulated by the ↵ subunit of the IKK complex, and the
NF-B inducing kinase (NIK). After the degradation of IB, released transcription
factor dimers can translocate to the nucleus and induce the expression of many
downstream genes which are involved in cell survival, proliferation, motility and
cytokine secretion [68, 69, 70].
MAPKs, the second major pathway activated by RANK-RANKL signaling, also
activate a variety of cellular responses involved in cell growth, proliferation, apoptosis
and inflammation. There are three main families of MAPKs discovered so far; extra-
cellular signal regulated kinases (ERKs), Jun amino-terminal kinases (JNKs) and
p38/stress-activated protein kinases (SAPKs). MAPKs are activated by a sequen-
tial phosphorylation process involving upstream protein kinases (MAPK kinases,
e.g. TAK1) which are activated by adaptor proteins recruited to the cytoplasmic
domain of RANK (TRAFs 2/5 and 6). The activated MAPKs lead to the translo-
cation of several transcription factors to the nucleus for upregulation of genes of
interest [71, 72, 73]. RANK-RANKL signaling also leads to the activation of PI3K
and Akt signaling, whose downstream target genes include many that are impor-
tant for survival, proliferation and growth, metabolism and angiogenesis, through
adaptor proteins Gab2 and Cbl [74, 75]. Taken together, the RANK-RANKL signal-
ing activates several downstream pathways through an intricate network of adaptor
proteins, which are all important in cell proliferation, apoptosis, di↵erentiation and
metabolism.
RANK is a master regulator in osteoclast di↵erentiation and thus is vital in bone
homeostasis [76]. Bone is crucial for the sustenance of skeletal strength, maintenance
of calcium reservoirs and the development of immune cells. Bone homeostasis is
maintained by the constant breakdown (resorption) and synthesis of the bone, by the
two main cell types osteoclasts and osteoblasts, respectively [77]. RANK is expressed
on osteoclast precursors, and when it binds the RANKL expressed by the stromal
cells in the bone, osteoclast maturation is triggered through the transcription factors
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c-fos, NFatc1/NFAT2 and NF-B [78]. Studies in RANK and RANKL knockout
mice showed that they develop osteopetrosis, a condition marked by abnormally
hardened bones, due to the lack of mature osteoclasts breaking the bone down [79].
In contrast, an overactivation of this pathway, for instance due to loss of OPG, leads
to osteoporosis, as a result of enhanced bone resorption [80].
Further studies in genetically manipulated mice have shown that RANK-RANKL
signaling is also important in organogenesis and immune reactions. RANK signaling
was shown to be involved in the development of secondary lymphoid tissues, through
its role on lymphoid tissue inducer cells during embryogenesis [81]. RANK and
RANKL knockout mice show a lack of peripheral lymph nodes and Peyer’s patches,
along with developmental abnormalities in the spleen [82]. RANK signaling is also
important for thymus development, especially for the development of medullary
tyhmic epithelial cells that are essential for the negative selection of autoreactive T
cells [83]. RANK and RANKL knockout mice also show defects in mammary gland
development [84]. In the immune system, RANK is expressed mainly on dendritic
cells (DCs) and RANKL on activated T cells. Macrophages and monocytes also
express RANK to some extent, and B cells can upregulate surface RANK expression
in response to CD40 ligation. RANK-RANKL ligation is important for DC survival
and cytokine production, indicating a possible role of RANK in antigen presentation
[85]. Absence of RANK signaling in vivo however can fully be compensated by
the closely related CD40 signaling, since these mice show no abnormalities in DC
development [86]. RANK and RANKL knockout mice show abnormalities in B and
T cell development, respectively, although it was later shown that the e↵ect of
RANK signaling on B cell development is not cell intrinsic, and rather stems from
a disturbed microenvironment in the bone marrow, where B cells develop [82, 87].
Overall, RANK-RANKL signaling was shown to be important in organogenesis,
bone homeostasis, immune system development and reaction to antigen, and plays
a central role in the osteo-immunological network.
1.3.2 Receptor Activator of NF-B and Pathology
Given its role in the activation of a variety of pathways, dysregulation of RANK
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signaling has been implicated in the development of several diseases. Mutations in
RANK have been linked to the development of bone diseases such as Paget’s dis-
ease or autosomal-recessive osteopetrosis [88, 89]. Disruption of the balance between
RANK/RANKL concentrations in the bone environment in favor of RANKL was
shown to cause osteoporosis in post-menopausal women [90]. Similarly, high RANKL
expression in the synovium is the cause of bone destruction in rheumatoid arthritis
[91].
Dysregulation of RANK-RANKL signaling has also been implicated in many
types of cancer. RANK expression on primary tumors is a poor prognostic marker
in breast cancer, and has been associated with bone metastasis [92]. Expression of
RANK on prostate cancer cells is also shown to aid in the metastasis to bone [93].
Giant cell tumors of bone are shown to overexpress RANK and RANKL [94]. Among
lymphoid malignancies, cultured Hodgkin’s lymphoma disease cells (Hodgkin and
Reed Sternberg cells) co-express RANK and RANKL on their surface, leading to an
autocrine positive feedback loop that enhances survival [95]. Multiple myeloma cells
are also shown to disrupt the RANKL/OPG balance in favor of RANKL, either
by expressing RANKL themselves or inducing the bone marrow stromal cells to
overexpress RANKL, leading to bone lesions in patients [96]. Chronic lymphocytic
leukemia (CLL) B cells have also been shown to have increased surface expression
of RANK and RANKL, which leads to the induction of IL-8 secretion in B-CLL
cells [97]. Strikingly, in 8% of ABC DLBCL patients mutations in RANK have
been observed. A frequent mutation is the A756G mutation that leads to an amino
acid change at position 240 from lsyine to glutamine (K240E), that is located in
the intracellular domain [61]. Yet, the functional consequences of this mutation is
largely unknown.
Given the e↵ect of dysregulation of the NF-B pathway on several B cell related
disorders, the occurrence of this RANK mutation in ABC DLBCL patients is in-
triguing. As the functional consequences of this mutation and of enforced RANK
signaling in B cell physiology or lymphomas have not yet been described, a study
was designed to investigate the role of the K240E mutation and abnormal RANK
signaling in B cells. The following chapter describes the objectives and methods of
the designed project.
Chapter 2
Research Objective
Aberrations in signaling pathways during di↵erent stages of B cell development
have diverse pathological repercussions such as autoimmune disorders or lymphoid
malignancies. Activating mutations in, or overexpression of, genes that induce sur-
vival, proliferation and prevent apoptosis, as well as inactivation of regulatory genes
have been demonstrated to result in lymphomagenesis. RANK, a receptor important
for both osteoclastogenesis and activation of the adaptive immune system, has been
shown to be mutated in 8% of ABC-DLBCL cases, whose characteristic is the con-
stitutive activation of NF-B. The recurrent A756G (K240E) mutation in RANK
was detected in 8% of these patients. The functional e↵ects of this mutation in B
cells in vivo and whether it drives or promotes the progress of B cell pathology in
general remain elusive. RANK signaling is shown to be upregulated in Hodgkin’s
lymphoma, as well as multiple myeloma and CLL. The exact signaling networks
through which the upregulation of RANK/RANKL promotes B-cell malignancies is
currently unknown.
Based on the frequent dysregulation of the RANK signaling pathway in di↵erent
entities of B-cell malignancies, this study aims to elucidate the role of the K240E
mutation and deregulated RANK signaling in B cell development and pathology.
The conditional gene targeting approach in mice was employed to tackle this ques-
tion. Human RANK(A756G) cDNA was introduced into the ubiquitously expressed
murine ROSA26 locus. A STOP cassette flanked by loxP sites was located in front of
the RANK cDNA, to ensure transcription would only occur after breeding with the
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Cre-transgenic mice of interest, and achieve tissue and time specific deletion of the
stop cassette. B-cell specific expression of RANK(A756G) was achieved by breed-
ing the Rosa26 targeted mice with CD19-Cre mice, since CD19 is a B-cell specific
surface molecule whose expression is initiated early in B cell development, following
the pro-B cell stage.
The objective of this study is, to utilize a mouse model that sheds light onto
the role of aberrations in RANK signaling in B cell biology. Identifying the mech-
anisms that are dysregulated upstream or downstream of RANK is also important
for therapeutical e↵orts in treating several B cell malignancies.
Chapter 3
Materials
3.1 Chemicals and Reagents
All chemicals and reagents were purchased from Sigma-Aldrich, unless stated
otherwise. For a detailed description of the reagents and their origin, see the “Meth-
ods” section.
3.2 Antibodies
3.2.1 Western Blot Antibodies
Name Company
↵-phospho-PLC 2 (Tyr1217; rabbit polyclonal IgG) Cell Signaling
↵-phospho-Akt (Ser473; rabbit polyclonal IgG) Cell Signaling
↵-phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204;
rabbit polyclonal IgG)
Cell Signaling
↵-phospho-SAPK/JNK (Thr183/Tyr185; rabbit poly-
clonal IgG)
Cell Signaling
↵- -Actin (mouse monoclonal IgG) Cell Signaling
↵-mouse IgG HRP-linked (horse polyclonal IgG) Cell Signaling
↵-rabbit IgG HRP-linked (goat polyclonal IgG) Cell Signaling
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3.2.2 Cell Stimulation
Name Company
Functional grade purified ↵-mouse CD3e (145-2C11) e-Bioscience
Functional grade purified ↵-mouse CD28 (37.51) e-Bioscience
A niPure rabbit ↵-Syrian Hamster IgG Jackson Immuno Research
3.2.3 Flow Cytometry Antibodies
Flow cytometry antibodies listed below were conjugated to one of the following
fluorochromes: phycoerythrin (PE), phycoerythrin cyanin 5 (PE-Cy5), phycoery-
thrin cyanin 7 (PE-Cy7), allophycocyanin (APC), allophycocyanin cyanin 7 (APC-
Cy7) or eFluor 506. Only the purified ↵-mouse CD16/32 antibody used for Fc re-
ceptor blocking was unconjugated.
Name Company
7-AAD Viability Staining Solution e-Bioscience
Annexin V Apoptosis Detection Kit e-Bioscience
Cell Trace Violet Cell Proliferation Kit ThermoFisher Scientific
Fixable Viability Dye eFluor 506 e-Bioscience
↵-mouse B220 (RA3.6B2) e-Bioscience
↵-mouse CD4 (GK1.5) e-Bioscience
↵-mouse CD5 (53-7.3) e-Bioscience
↵-mouse CD8 (53-6.7) e-Bioscience
↵-mouse CD16/32 (93), purified e-Bioscience
↵-mouse CD19 (1D3) e-Bioscience
↵-mouse CD25 (3C7) e-Bioscience
↵-mouse CD44 (IM7) e-Bioscience
↵-mouse CD62L (MEK-14) e-Bioscience
↵-mouse CD80 (16-10A1) e-Bioscience
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↵-mouse CD86 (GL1) e-Bioscience
↵-mouse CD93 (AA4.1) e-Bioscience
↵-mouse CD117 (c-kit) (2B8) e-Bioscience
↵-mouse CD138 BD Pharmingen
↵-mouse Ki67 (SolA15) e-Bioscience
↵-mouse IgM (II/41) e-Bioscience
↵-mouse MHCII (M5/114.15.2) e-Bioscience
↵-mouse RANK(CD265, 9A725) ThermoFisher Scientific
↵-mouse RANKL(CD254, IK22/5) e-Bioscience
3.2.4 Direct Immunofluorescence Antibodies
Name Company
↵-mouse IgG (Alexa Fluor 488 goat polyclonal) ThermoFisher Scientific
↵-mouse IgM (Alexa Fluor 647 goat polyclonal) ThermoFisher Scientific
3.3 Primers
All primers were synthesized by Sigma-Aldrich or Eurofins Scientific. All primers
that were not previously published were designed using the freeware ApE.
3.3.1 RANK(K240E) cDNA Generation and Site-directed
Mutagenesis
Name 5’-3’ Sequence
hRANKF ATGCGGTTTGCAGTTCTTCTC
hRANKR ACTCCTTATCTCCACTTAGG
xhoI fwd CTCGAGAACAACTTTATCCTCCTGGAA
ecoRI rev GAATTCAGGTGCGGGAGCGGTTAGTTC
xhoI fwd CTCGAGAACAACTTTATCCTCCTGGAA
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ecoRI rev GAATTCAGGTGCGGGAGCGGTTAGTTC
fwd ascI GGCGCGCCCCACCATGAACAACTTTATCCTCCTGG
rev ascI GGCGCGCCAGGTGCGGGAGCGGTTAGTTC
kd fwd GTGAAAACCGTGGCTGTGAGAATACTGAAAAACGAGGCC
kd rev GGCCTCGTTTTTCAGTATTCTCACAGCCACGGTTTTCAC
ph fwd CCCTCGAACTTTAAAGTCTGCTTCTTTGTGTTAACC
ph rev GGTTAACACAAAGAAGCAGACTTTAAAGTTCGAGGG
3.3.2 Southern blot Amplification Probe
Name 5’-3’ Sequence
probe fwd GATCAAAACACTAATGAACTT
probe rev TTAATTAAAACGAATATTTGGAAT
3.3.3 Genotyping
Name 5’-3’ Sequence
Cre7 TCAGCTACACCAGAGACGG
CD19c AACCATTCAACACCCTTCC
CD19d CCAGACTAGATACAGACCAG
RANKgeno ACACTGGCTAGGAGAGATTCCTTC
Longgeno ACTCGGGTGAGCATGTCTTTAATC
Shortgeno GTGATCTGCAACTCCAGTCTTTCTA
IRESgeno ATACGCTTGAGGAGAGCCATTTG
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3.3.4 Real-Time PCR
Name 5’-3’ Sequence
ActinF AGACCTCTATGCCAACACAG
ActinR TCGTACTCCTGCTTGCTGAT
APCF CTTGTGGCCCAGTTAAAATCTGA
APCR CGCTTTTGAGGGTTGATTCCT
Bcl-2F CTGCACCTGACGCCCTTCACC
Bcl-2R CACATGACCCCACCGAACTCAAAGA
CyclinD1F GCGTACCCTGACACCAATCTC
CyclinD1R CTCCTCTTCGCACTTCTGCTC
IKK- F AGCTGTCCTTACCCTGCTGA
IKK- R TGCTGCAGAACGATGTTTTC
MALT1F GGTGGATGTGTATGAATTGACCA
MALT1R ACCGTGCCCTGCATAATATAAC
PTENF CTTTTTCTTCAGCCACAGGC
PTENR GCAGTTAAATTTGGCGGTGT
3.3.5 Ig Clonality and Somatic Hypermutation PCRs
Name 5’-3’ Sequence
JH4 AAAGACCTGCAGAGGCCATTCTTACC
DSF AGGGATCCTTGTGAAGGGATCTACTACTGTG
VHA GCGAAGCTTA (AG) GCCTGGG (AG) CTTCAGTGAAG
VHB GCGAAGCTTCTCACAGAGCCTGTCCAATCAC
VHC GCGAAGCTTTCTCAG (AT) CTCTGTC (CT) CTCACC
VHD GCGAAGCTTCTGCAGTCTGGAGGTGGCCTG
VHE GCGAAGCTTGTGGAGTCTGGGGGAGGCTTA
VHF GCGAAGCTT (AT) CTGGAGGAGGCTTGGTGCAA
VHG GCGAAGCTTGGAGAGACAGTCAAGATCTCC
DQ52 ACGTCGACGCGGACGACCACAGTGCAACTG
DFS ACGTCGACTTTTGT (GC) AAGGGATCTACTACTGT
JH4E AGGCTCGTAGATCCCTACACAG
JH4A GGGTCTAGACTCTCAGCCGGCTCCCTCAGGG
Chapter 4
Methods
4.1 Polymerase Chain Reaction (PCR)
The polymerase chain reaction is used to amplify nucleotide sequences of interest.
It utilizes two or more forward and reverse primers that bind to the single-stranded
DNA in the desired region of the genome and a DNA polymerase to synthesize
the fragment aimed to be amplified. A PCR contists of three phases; denatura-
tion, where the double-stranded DNA input is denatured into single-stranded DNA
molecules with the help of high temperatures that destabilize DNA; annealing, where
the designed primers bind to the region of interest at a lower temperature; and ex-
tension where the DNA polymerase synthesizes the DNA fragment of interest, by
adding templated nucleotides from the primer-binding site on. These three steps are
repeated as several cycles, typically 30 to 35 times, to maximize the yield of the
reaction [98].
In the work at hand, PCRs have been used for several purposes, such as geno-
typing mice, Real-Time PCR, determining the clonality of the B cell repertoire of
RANK(A756G) mice, determining the level of somatic hypermutation in transgenic
B cells and molecular cloning. Unless stated otherwise, the amplification reactions
were set up with 0.2mM dNTP (Bioline), 0.2 µM of each primer, 50ng template,
0.04U/µl of Phire HotStart II DNA polymerase (ThermoFisher Scientific) in reac-
tion bu↵er (ThermoFisher Scientific). Reaction volumes were chosen to be 25 or 50
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µl, depending on the application. All reactions were implemented in a PCR ther-
mocycler (Bio-Rad). Further specifications of reactions for di↵erent applications are
given in the respective sections. PCR products were visuzalied by agarose gel elec-
trophoresis, as previously described [99].
4.2 Genotyping PCR
Presence of the RANK(A756G) and CD19-Cre alleles in mouse progeny was de-
termined through amplification of transgene-specific sequences by genotyping PCR.
For this purpose, DNA was isolated from the tails of 3-week old mice by using
the Wizard SV Genomic DNA Purification System Kit (Promega). The allele con-
taining ROSA26loxSTOPlox-RANK(A756G) was detected by a 4-primer PCR (long, short,
IRES, RANK genotyping primers), capable of amplifying both the sequence of the
recombined locus with the IRES-RANK primer pair and the wildtype locus with the
long-short primer pair. The recombinant locus yields at 570 base-pair band whereas
the wildtype locus yields a 300 base-pair band. The Cre allele of CD19-Cre mice
was detected utilizing a 3-primer PCR with CD19c/CD19d/Cre7 primers. The re-
combinant and wiltype loci yield bands of size 715 base-pair and 492 base-pair,
respectively. The PCR conditions for RANK and CD19-Cre genotyping PCRs are
as follows:
RANK genotyping PCR
Phire HotStart activation 30”, 98 C
35 cycles denaturation: 5”, 98 C
annealing: 5”, 62 C
extension: 15”, 72 C
End elongation: 1’, 72 C
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CD19-Cre genotyping PCR
Phire HotStart activation 30”, 98 C
35 cycles denaturation: 5”, 98 C
annealing: 5”, 57 C
extension: 15”, 72 C
End elongation: 1’, 72 C
4.3 Real-Time PCR
RNA was freshly isolated from sorted RANK(A756G) expressing and wildtype B
cells by using RNeasy Mini Kit (QIAGEN), according to the manufacturer’s instruc-
tions. RNA concentration of the samples was determined by NanoDrop. (Thermo
Fischer Scientific Inc.) RNA was reverse transcribed using SuperScript II (Invitro-
gen) according to the manufacturer’s instructions. Briefly, with 20µl reaction of 100
ng- 1 µg total RNA, 0.5mM dNTPs, 250ng random primers, 5mM DTT, and 10U/µl
of SuperScriptTM II RT was set up. The generated cDNA was used in duplicates or
triplicates for RT-PCR reactions, with primers that span exon-exon boundaries to
ensure cDNA-specific amplication. The qPCR Core Kit for SYBR Green I (Roche)
was used to perform RT-PCR. Gene expression patterns were normalized to the
housekeeping gene, Actin. The reaction was carried out in a Light Cycler 480 II
(Roche) and analyzed for quality using melting curves. The conditions for the am-
plification reaction are as follows:
HotGoldStar activation 10’, 95  C
45 cycles denaturation: 15”, 95  C
annealing: 20”, 60  C
extension: 40”, 72  C
4.4 Ig Clonality PCR
The clonality of the B cell repertoire in mice was determined by PCR, as de-
scribed previously [100]. Briefly, GFP+ B cells and CD19+ B cells were sorted
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from RANK(A756G)CD19-Cre and CD19-Cre mice, respectively. B cell genomic DNA
was isolated using DNeasy Blood&Tissue Kit (QIAGEN), according to the manu-
facturer’s instructions. A clonality PCR with the primer pair DFS-JH4 was imple-
mented using the Expand Long Template PCR System (Roche), according to the
manufacturer’s instructions. DFS primer hybridizes to the 5’ recombination signal-
ing sequence of all murine DH segments, whereas JH4 hybridizes downstream of
the JH4 segment, leading to the amplification of four possible DJH recombinations
with a “ladder” appearance on the agaorse gel in a polyclonal B cell repertoire. The
conditions of the PCR reaction are as follows:
94 C 2’
35 cycles of:
94 C 1’
60 C 90”
68 C 2’ (3” increment)
68 C 10’
4.5 Detecting Somatic Hypermutation Frequency
Somatic hypermutation frequency was detected implementing a PCR method
as previously described [101]. Briefly, a set of 5’ consensus primers (specified in the
“Materials” section) that are homologous to murine VH or DH genes in combination
with a 3’ primer downstream of the JH4 cluster are used to amplify many several
fragments at once. The product of this first reaction is then used for a second
PCR, utilizing a nested PCR approach, where the amplified product is analyzed in
separate reactions with a single VH or DH primer in combination with a 3’ nested JH
primer. GFP+ B cells and CD19+ B cells of RANK(A756G)CD19-Cre and CD19-Cre
mice, respectively were sorted and their genomic DNA was isolated as mentioned in
section 4.4, and 50 ng of it was used for the PCR, where the Expand Long Template
PCR System (Roche) was used according to the manufacturer’s instructions. The
PCR product was run on agarose gel, and the bands were excised and cleaned up
using peqGOLD gel extraction kit (Peqlab Biotechnologie). The extracted DNA
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fragments were cloned into a TOPO TA vector using the TOPO TA Cloning Kit
for Sequencing (ThermoFisher Scientific) according to manufacturer’s instructions.
The cloned DNA fragments were sequenced by Source BioScience and the sequencing
results were analyzed using ApE freeware and the IMGT/V-QUEST database.
4.6 Molecular Cloning and Retroviral Transduc-
tion
In the presented work, molecular cloning technique was applied to generate retro-
viral expression vectors of wildtype RANK and RANK(A756G), using the vector
pMIGR1 as well as the pRosa26loxSTOPlox-RANK(A756G) targeting vector for the gener-
ation of a mouse knockin, as described previously [102, 103]. The generation of the
pRosa26loxSTOPlox-RANK(A756G) vector and the retroviral expression vector for wild-
type RANK was done by Dr. Nathalie Knies. Briefly, cDNA of interest was am-
plified by PCR, using a DNA polymerase with proofreading capability (Phusion
High Fidelity DNA Polymerase-ThermoFisher Scientific), flanked by restriction en-
donuclease recognition sites. This cDNA insert was ligated to a TOPO TA vector,
according to the manufacturer’s instructions. One Shot Top10 chemically compe-
tent E.coli (Invitrogen) were used for all TOPO TA Cloning procedures. Following
the initial ligation reaction, 2 µg of the TOPO TA vector containing the insert was
digested with the restriction enzymes of interest. Depending on the application, 2
µg of the pRosa26 targeting vector or pMIGR1 was also digested with the same
restriction enyzmes (overnigt at 37 C), and the product was run on an agarose gel
the following day. Digested fragments of the desired insert and the desired end vec-
tor were extracted from the gel using the QIAquick Gel Extraction Kit (Qiagen),
according to the manufacturer’s instructions. The purified vector backbone and in-
sert were then ligated using T4 ligase (Invitrogen), according to the manufacturer’s
instructions. The ligation product was then used for transformation of Subcloning
E ciencyTM DH5alphaTM chemically competent E.coli (Invitrogen) according to
the manufacturer’s protocol, and the successfully transformed bacteria were selected
for by using ampicillin containing LB agar plates, as ampicillin resistance gene beta-
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lactamase was the selection marker of both target vectors. For the generation of
pRosa26loxSTOPlox-RANK(A756G) targeting vector, only a single restriction enzyme was
used to linearize the vector backbone, therefore dephosphorylation of the two ends
of the backbone was performed by incubating the digested vector in 0.025U/µl Calf
Intestinal Alkaline Phosphatase (ThermoFisher Scientific) at 37 C for 1h, to increase
ligation e ciency, prior to ligation.
The pMIGR1 vector used for retroviral transduction of Bal17 cells with wildtype
RANK and RANK(A756G), is an MSCV based vector, carrying an IRES (internal
ribosomal entry site)-GFP sequence, which enables GFP expression and thus allows
fluorescence assisted cell tracking of the cells that contain the vector. The human
mutant RANK cDNA sequence was generated by a site-directed mutagenesis PCR
utilizing the primer pair hRANK forward and hRANK reverse, as described in the
“Materials” section. The amplification conditions for the reaction were 95 C for 1’,
18 cycles of 95 C for 50”, 60 C for 50”, 68 C for 8’, followed by an end-extension
step at 68 C for 7’, utilizing the Phusion DNA polymerase. The amplified insert was
cloned into the pMIGR1 vector as described above. After successful cloning of the
insert and verification by sequencing data, the construct was retrovirally transduced
to Bal17 cells. Retroviral transduction is the process by which nonviral gene is in-
troduced into a mammalian cell through a virus. The introduced DNA sequence is
integrated into the genome of the cellular host, therefore leading to stable expression
of the gene [104]. For this purpose PhoenixE packaging cells were used to produce
the retroviral particles carrying the RANK gene. PhoenixE cells that carry the viral
genes gag, pol, and env needed for retroviral particle assembly were transiently trans-
fected with the retroviral constructs containing mutant or wildtype RANK, using
the TransIT-LT1 Transfection Reagent (Mirus Bio LLC), according to the man-
ufacturer’s instructions. 6 hours after transfection, the medium on the PhoenixE
cells were changed to PhoenixE culture medium and supernatant containing viral
particles was collected and filtered (0.45 µm) at 24 and 48 hours post-transfection.
1x106 Bal17 cells were resuspened in viral supernatant, supplemented with 10 µM
polybrene, which is a cationic polymer that enhances viral adsorption to the plasma
membrane of the cell. The cells were then spin infected by centrifugation (2400rpm,
32 C, 90min) and cultured for 12 hours, followed by another round of spin infection.
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Transduction e cieny was determined by flow cytometry, according to GFP expres-
sion, and the GFP+ Bal17 cells were subjected to FACS, before use in downstream
applications.
4.7 Southern Blot
Electroporation of embryonic stem cells (ESC) and Southern blot for the screen-
ing of ESCs positive for Rosa26 locus recombination was performed by Dr. Nathalie
Knies, as described previously [105]. Briefly, cultured ESCs were electroporated with
the pRosa26loxSTOPlox-RANK(A756G) vector, and incubated overnight. Genomic DNA
was isolated by phenol/chloroform extraction. 20 µg of DNA was digested with
1.6U/µl XbaI (New England Biolabs) overnight at 37 C, follwed by slow agarose
gel electrophoresis. The gel was then depurinated in 0.25M HCl; denatured in 1.5M
NaCl with 0.5M NaOH; and neutralized in 1M Tris with 1.5M NaCl (pH 7.4) Single
stranded DNA molecules obtained after this procedure were transferred overnight
onto a positively charged nylon membrane (HYBOND-nylon membrane, GE Health-
care) with capillary force. The DNA was crosslinked to the membrane by shortwave
ultraviolet radiation (254nm, 120J) in a CL-1000 Ultraviolet Crosslinker (UVP).
Rosa26 probe was labeled radioactively, and purified on Micro SpinTM S-200 HR
columns (GE Healthcare), according to the manufacturer’s instructions. The mem-
brane was incubated in 40 ng of radioactively labeled Rosa26 probe in Church bu↵er
(1mM EDTA, 0.25M sodium phosphate bu↵er (pH7.2), 7% SDS (w/v), 1% BSA
(w/v)), overnight at 65 C. The membrane was washed the following day with wash
bu↵er ((2x SSC, 0.1% SDS (w/v)) and (0.2x SSC, 0.1% SDS (w/v)) and visual-
ized with a PhosphorImagerTM (Molecular Dynamics). The image was analyzed
with ImageQuantT M software. ESC clones positive for Rosa26 homologous re-
combination with best morphology and growth characteristics were injected into
C57BL6/J blastocysts and transferred to foster mice as previously described. Blas-
tocyst microinjection and generation of knockin mice with germline transmission of
the targeted allele was performed by Polygene.
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4.8 Cell Culture
The mouse mature B cell lymphoma cell line Bal17, freshly isolated primary B
cells and CD4+ T cells were cultured in RPMI-1640 medium supplemented with 10%
fetal bovine serum (FBS) (v/v) (Capricorn), 1% pen/strep (v/v), 1% L-glutamine
(v/v) and 0.1% 2-mercaptoethanol (v/v). ST2 mouse bone marrow stromal cell
line and PhoenixE packaging cells were kept in DMEM, supplemented as described
above. Bal17 cells were split 1:10 every 3 days and ST2 and PhoenixE cells were
split 1:5 every two days by trypsinizing (1% Trypsin/EDTA (v/v)). All cells were
cultured under standard cell culture conditions; at 37 C, 5% CO2 and 95% humidity.
The cells were frozen for conservation in RPMI or DMEM medium, supplemented
with 10%DMSO (v/v) and 10% FBS (v/v). Freshly isolated primary lymphocytes
were prepared in RPMI-1640 medium supplemented with 5% fetal bovine serum
(FBS) (v/v) (Capricorn), 1% pen/strep (v/v), 1% L-glutamine (v/v) and 0.1% 2-
mercaptoethanol (v/v), until cultured. All media and supplements except for the
FBS were purchased from Gibco.
4.9 Cell Purification
Primary cells from spleen, lymph nodes and Peyer’s patches were isolated by
mashing organs through 100 and 70 µm filters in preparation medium as described
above. Peritoneal cavity was washed out with the help of a needle with preparation
medium for cellular content. Bone marrow cells are isolated by flushing the marrow
out of the bone with the help of a needle and preparation medium, and mashing
through a 100 µm filter. All isolated samples underwent a red blood cell lysis pro-
cedure, and were resuspended in 1 ml red blood cell lysis bu↵er (G-DEX11, Intron
Biotechnology) for 5 minutes. Following this the cells were counted by Trypan Blue
staining (Trypan Blue Stain 0.4%(w/v), Gibco) and CD19+ B cells or CD4+ T
cells were enriched by negative magnetic labeling, as described by Miltenyi Biotec
(Mouse CD4+ T Cell Isolation Kit and Mouse B Cell Isolation Kit, Miltenyi Biotec).
In this system of magnetic separation (MACS), the cells of interest accumulate in
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the flow-through, untouched and therefore unactivated. The flow-through containing
the cells of interest was centrifuged at 400g for 5 minutes to collect the cells. Cells
were washed with preparation medium and used for further analysis.
4.10 Cell Stimulation
RANK(A756G) expressing or wildtype B cells and CD4+ T cells were purified
by fluorescence-activated cell sorting or magnetic labeling, respectively. After the
purification step the cells were rested for 2 hours at 37 C, with a concentration of
20x106 cells/ml, in resting medium RPMI, containing 1% BSA, 1% pen/step, 1% L-
glutamine and 0.1% 2-mercaptoethanol. Following the resting, the cells were washed
with PBS and resuspended at a concentration of 2x106/ml. CD4+T cells were stim-
ulated on a 96 F-well plate pre-coated with A niPure rabbit ↵-syrian hamster IgG
(H+L) crosslinking antibody overnight at 4 C (1 µg/ml final concentration), and
treated with functional grade purified ↵-mouse CD3e (5 µg/ml final concentration)
for one hour at 37 C. 2x105 CD4+T cells per well were added to the wells with ↵-
mouse CD28 (1 µg/ml final concentration) and incubated at 37 C for 1 to 96 hours.
RANK(A756G) expressing or wildtype B cells were stimulated on 96 F-well plates
or 6-well plates after sorting, and incubated with 100 ng/ml (final concentration)
mouse recombinant RANKL (R&D systems), 2 µg (final concentration) neutralizing
antibody purified mouse ↵-RANKL (eBioscience) or 0.5 µM (final concentration)
CpG (Invivogen) for 1 to 48 hours at 37 C.
Bal17 cells were retrovirally transfected, fluorescently sorted for GFP+ cells and
kept under normal cell culture conditions until stimulation. 2x106 Bal17 cells were
stimulated with 100 ng/ml (final concentration) mouse recombinant RANKL for 5
minutes to 48 hours at 37 C. All stimulated cells were spun down at 400g for 5
minutes and washed with PBS once, before use for downstream applications.
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4.11 Preparing Cell Lysates andWestern Blot Anal-
ysis
Whole cell lysates for protein analysis were prepared by lysing 5x106 B cells in ice
cold CHAPS bu↵er, supplemented with phosphatase inhibitors (50mM NaF, 0.1mM
Na3VO4) and protease inhibitors (EDTA free Protease Inhibitor Cocktail Tablets,
Roche Diagnostics). Concentrations of lysates were determined spectrophotometri-
cally, by implementing the Bradford Assay (Bio-Rad), according to the manufac-
turer’s instructions. The lysates were then denatured in SDS sample bu↵er at 95 C
for 5 minutes before loading onto the polyacrylamide gel, as described before [106].
Polyacrylamide gel electrophoresis method separates proteins across an electrically
charged field based on their molecular weight and charge. The separated proteins
were transferred onto a nitrocellulose membrane (Amersham Protran, GE Health-
care) electrophoretically with a wet-blotting approach in transfer bu↵er. Following
transfer, membranes were blocked in 5% skim milk powder in TBST and incubated
overnight with specific primary antibodies diluted 1:1000 in 5% BSA in TBST.
HRP-conjugated secondary antibodies (1:5000 in 5% skim milk powder in TBST)
were added the next day after washing the membranes with TBST. For chemilu-
miniscent detection, the detection systems LumigenTM TMA-6, Solution A+B (GE
Healthcare) or Detection Reagent 1+2/Peroxid Solution (Thermo Scientific, Pierce)
were utilized. The antibodies used for Western blotting are listed in the “Materials”
chapter. The bu↵ers used in this procedure are as follows:
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CHAPS bu↵er 10mM Tris (pH7.5)
1mM MgCl2
1mM EGTA
10% glycerol (v/v)
0.5% CHAPS (w/v)
SDS sample bu↵er 62.5mM Tris/HCl (pH6.8)
2% SDS (w/v)
10% glycerol (v/v)
5% 2-mercaptoethanol (v/v)
0.02% bromphenol blue (w/v)
SDS-PAGE running bu↵er 25mM Tris (pH 8.3)
2M glycine
1% SDS (w/v)) at 120V
Transfer bu↵er 50mM Tris (pH 8.5)
40mM glycine
0.03% SDS (w/v)
20% methanol (v/v) added freshly (at 350 mA for 90’)
TBST 0.025% Tween-20 (v/v)
20mM Tris (pH7.4)
137mM NaCl
4.12 Enzyme-Linked Immunosorbent Assay (ELISA)
The ELISA method relies on chemiluminescent detection of antigen-antibody
interactions on a plate [107]. Detection of serum immunogloublins of transgenic and
wildtype mice was performed using the Mouse Immunoglobulin Panel, manufactured
by Southern Biotech. Briefly, the sera obtained from mice were diluted 1:500 with
blocking bu↵er, a 96-well flat bottom plate was incubated overnight at 4 C with
1:100 diluted capture antibody in coating bu↵er (goat- ↵mouse Ig (H+L), Southern
Biotech) and washed three times the following day. Blocking bu↵er was added to the
plate and the plate was incubated for 1 hour. After washing the plate 3 times, 1:3
serial dilutions of the pre-diluted serum were done and the plate was incubated at
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room temperature for 1 hour, and washed 3 times afterwards. Detection antibody,
1:250 diluted in blocking bu↵er was added on the wells and the plate was incubated
for 1 hour at room temperature. Following the incubation, the plate was washed 5
times and substrate bu↵er (with freshly added phosphatase substrate from Sigma
Aldrich) was added on the wells.
Time course measurements (5, 10, 15 and 20 minutes) were performed in a mi-
croplate reader (Tecan Group), using the Magellan software to detect the serum
immunoglobulin levels. Measurements utilized the transmission of light during the
alkaline phosphatase reaction at 450 nm. The reference wavelength for background
noise was 570 nm. The serum concentrations of immunoglobulins were determined
by standard-curve calculations. The contents of the bu↵ers used are as follows:
Coating bu↵er 1 pack ELISA/ELISPOT Coating bu↵er powder
(Southern Biotech) dissolved in 1 L H2O
Blocking bu↵er PBS,1%BSA
Washing bu↵er PBS, 0.05% Tween
Substrate bu↵er 100 ml dH2O, 12 ml Di-ethanol, 30 µl MgCl2
pH 9.8, adjusted with 18.5% hydrochloric acid
The detection of autoantibodies in sera of transgenic and wildtype mice was
performed using Autoimmune ELISA kits purchased from Alpha Diagnostic Inter-
national. The sera obtained from mice were initially diluted 1:50 and the manufac-
turer’s instructions for the kit were followed.
4.13 Flow Cytometry and Fluorescence-activated
Cell Sorting (FACS)
Flow cytometry method is based on computer-processed light scatter and fluo-
rescent signals received from a fluorescently labeled single cell suspension after laser
excitation. This method can be used to determine the size and granularity of cells,
as well as expression of surface markers, which can be fluorescently labeled using
antibodies against certain epitopes of surface molecules conjugated to fluorescent
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molecules. Flow cytometry can also be used for detection of intracellular proteins,
after proper cell fixation and permeablization methods are applied [108].
In this study, flow cytometry is used to perform immunophenotyping of lympho-
cytes isolated from spleen, lypmh nodes, Peyer’s patches, peritoneal cavity and bone
marrow of mice. After cells were prepared as explained in section 4.9 and counted,
they were resuspended and washed in FACS bu↵er (PBS, 3% FBS) (400g, 5’, 4 C)
and incubated with 1:200 diluted CD16/32, to block free Fc receptors, washed in
FACS bu↵er again and incubated for 20’ at 4 C with respective fluorescently conju-
gated antibodies against surface molecules. The antibodies were diluted either 1:200
or 1:400. All antibodies were diluted in FACS bu↵er. The cells were acquired using
a FACSCantoII flow cytometer.
The FACS method was implemented to sort and enrich certain cell types labeled
fluorescently. The transgenic B cells were sorted regularly using GFP expression for
downstream applications. Cells isolated from the spleen or lymph nodes of wildtype
mice were stained with a fluorescent CD19 antibody, as documented in the “Ma-
terials” section and sorted for B cells. All sorting experiments were performed on
a FACSAria III sorter. The cells were sorted directly into filtered sterile FBS and
washed with FACS bu↵er before use in downstream applications.
4.14 Histology
Preparation of organs for histology and histological analysis were done in col-
laboration with Professor Wilko Weichert (DKFZ, Heidelberg). Briefly, the isolated
organs were fixed in 4% paraformaldehyde overnight and para n embedded. Tis-
sue sections of thickness 3–5µm were prepared and cell nuclei and tissue structure
were visualized by haematoxylin&eosin (H&E) staining. To visualize immunoglob-
ulin complexes in kidneys of transgenic mice, immunofluorescence with scanning
electron microscopy from kidneys fixed in 4% paraformaldehyde was performed by
Dr. Stephan Macher-Go¨ppinger (DKFZ, Heidelberg).
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4.15 Immunofluorescence
Immunofluorescence to detect anti-nuclear autoantibody presence in transgenic
mice was performed together with Torben Gehring. Hep-2 slides were purchased
from Euroimmun AG. The sera obtained from transgenic and wildtype mice were
diluted 1:100 in PBS, applied on the slides and incubated at room temperature
for 30 minutes. Slides were washed with PBS and detection antibodies (as listes in
“Materials” section) were added on the slides. After 30 minutes of incubation at
room temperature in the dark, the slides were washed and covered with coverslips.
A Leica DMRBE fluorescent microscope was used to photograph the slides. The
photographs were not modified with any software.
4.16 Statistical Analysis
Statistical significance for the results was analyzed with the unpaired two-tailed
Student’s t test and ordinary one-way ANOVA, using Prism Version 6.0, Graphpad
Software Inc. Di↵erences between analyzed groups were labeled as significant if p-
value 0.05.
Chapter 5
Results
5.1 RANK(A756G) Mutation in vitro
To investigate the RANK(A756G) mutation and its potential role in dysregu-
lation of signaling, retroviral transduction experiments with RANK(A756G) were
performed. The Bal17 cell line, a murine cell line derived from a mature B cell lym-
phoma was used as the cellular system for enforced RANK(A756G) expression. The
amino acid change lysine to glutamic acid at position 240 (K240E) was introduced
by site-directed mutagenesis to wildtype RANK (nucleotide change A756G). Figure
5.1 depicts the wildtype and mutant RANK, with the position of the mutation.
Retroviral expression vectors were generated by cloning the human RANK(A756G)
and wildtype RANK cDNA into the pMIGR1 vector, which contains an internal ri-
bosomal entry site (IRES) and the coding sequence of eGFP, enabling the tracking
of infected cells by flow cytometry.
Once RANK(A756G), wildtype RANK or empty pMIGR1 vectors were retrovi-
rally introduced in Bal17 cells, the cells were sorted for GFP+ cells to select the
successfully transduced cells. The transduced cells were then incubated in culture
with or without recombinant mouse RANKL (100 ng/ml) for one hour. This time-
point was chosen after initial timecourse experiments ranging from 5 minutes to
48 hours. After stimulation, surface expression of B cell activation markers were
analyzed by flow cytometry. Unstimulated cells that are infected by both wildtype
41
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Figure 5.1: Schematic depiction of RANK(A756G) mutation. Red arrow
indicates mutation. Motif 1 PFQEP(369-373), Motif 2 PVQEET(559-564) and Motif
3 PVQEQG(604-609) are TRAF binding motifs, and IVVY is a recently described
TRAF independent motif, cooperating with TRAF binding motifs to promote osteo-
clastogenesis. These four motifs enable RANK to mediate its downstream functions.
RANK and RANK(A756G) showed a marginal increase in the expression of the
surface activation marker CD80 compared to cells infected with empty pMIGR1,
whereas surface MHCII levels are similar in all three conditions. In response to stim-
ulation with RANKL for 1 hour however, RANK(A756G) expressing Bal17 cells had
slightly higher surface expression of both CD80 and MHCII, compared to Bal17 cells
that are expressing wildtype RANK, thus showing increased B cell activation upon
RANKL stimulation in RANK(A756G) expressing Bal17 cells and indicating gain
of function (Figure 5.2).
5.2 Mouse Model of Conditional RANK(A756G)
Expression
5.2.1 Targeting of the ROSA26 Locus
Since RANK(A756G) mutant induces slightly stronger B-cell activation than
wildtype RANK upon RANKL stimulation, this mutant form of RANK was used
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Figure 5.2: RANK(A756G) expression in Bal17 cells leads to marginally
higher B cell activation. Bal17 cells transduced with RANK(A756G), wildtype
RANK or empty pMIGR1 vector as control were sorted for GFP and stimulated or
not stimulated with 100 ng/ml recombinant mouse RANKL for 1 hour, and analyzed
for the expression of B cell surface activation markers by flow cytometry. Level of
RANK surface expression is in cells transduced with wildtype and mutant RANK is
the same, ruling out any di↵erences in outcome due to di↵erent RANK expression
levels. Data shown are representative of four experiments.
to study enforced RANK signaling in vivo. For this purpose, a genetically mod-
ified mouse model was generated by the conventional endogenous ROSA26 locus
targeting.
The endogenous murine ROSA26 locus has been well characterized and is widely
used for the generation of genetic knock-in mouse models. It is located on chromo-
some 6 and contains three exons. ROSA26 is shown to have ubiquitous promoter
activity and is expressed in moderate levels. Insertion of the desired gene into this
locus proceeds via homologous recombination and is considerably e cient due to
high frequencies of recombination in this area. In addition, homologous recombina-
tion events in this area have been shown to have no phenotypic e↵ect on the mouse
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[109].
The targeting vector was generated by cloning the RANK(A756G) cDNA into
a previously described pROSA26 targeting vector after AscI digestion. The consen-
sus sequence CCACC was added directly before the start codon of RANK(A756G)
to ensure optimal translation initiation. The RANK(A756G) cDNA was positioned
downstream of an adenovirus splice acceptor site (SA), followed by a neomycin re-
sistance stop cassette (NEO-STOP), flanked by loxP sites on both sides. An IRES-
eGFP cassette flanked by an FRT site (IRESeGFP), and a polyadenylation sequence
(pA) were inserted downstream of the RANK(A756G) cDNA. Homologous recom-
bination of the targeting vector into the locus was achieved by the “short-arm” and
“long-arm” of homology on the vector, which contained sequences identical to the
ones surrounding the site of integration within intron 1.
The occurrence of correct recombination in targeted embryonic stem cells was
visualized by Southern blot. Xba-I digested genomic DNA was separated by size
through an agarose gel and then was exposed to a 5’ probe, which enables the
detection of a 4.6 kb DNA fragment for the WT allele and a 9.2 kb DNA frag-
ment for the allele that contains the correctly insterted targeting vector. Figure
5.3 depicts the targeting strategy and shows a representative embryonic stem cell
clone with successful targeting. Breeding of the germline transmitting chimeras with
C57BL/6 mice lead to the generation of the ROSA26loxSTOPlox-RANK(A756G)
mouse strain, carrying the RANK(A756G) cDNA heterozygously in the ROSA26
locus. Transcription of RANK(A756G) is only possible after breeding with Cre-
transgenic mice, when the loxP-flanked NEO-STOP cassette is excised from intron
1. The SA site upstream of the RANK(A756G) cDNA sequence enables the correct
splicing of the stop cassette, leading to the transcription of an RANK(A756G)-IRES-
eGFP biscistronic mRNA. The IRES site enables the translation of eGFP protein
from the bicistronic transcript, and the RANK(A756G) is translated starting from
the start codon. The green fluorescence provided by the eGFP protein enables de-
tection of cells that express RANK(A756G) by flow cytometry analysis, and allows
cell tracking, throughout the life of a transgenic mouse.
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Figure 5.3: Generating the RANK(A756G) knockin strain and targeting
of the ROSA26 locus (A) RANK(A756G) targeting strategy. IRES, internal ri-
bosomal entry site; NEO, neomycin; pA, poly(A); SA, splice acceptor. The wildtype
ROSA26 locus, the targeting vector, and the ROSA26 locus upon homologous re-
combination are depicted. (B) Southern blot analysis. Lanes 1 and 2 show genomic
DNA from wildtype and transgenic mice. The size of the fragment showing the WT
ROSA26 locus is 4.6 kb, the recombined locus is 9.2 kb, and Cre-mediated removal
of the STOP cassette results in an 8.7-kb fragment.
5.2.2 B cell-specific expression of RANK(A756G)
In order to express RANK(A756G) in a B cell-specific manner, transgenic ROSA26
loxSTOPlox-RANK(A756G) mice were bred with CD19-Cre mice, which enabled the exci-
sion of the NEO-STOP cassette only in cells with an active CD19 promoter, namely,
B cells in the pre-B cell stage and onwards, allowing RANK(A756G) expression
early in the life of a B cell. Figure 5.4A shows a representative breeding scheme
for this mouse model. Excision of the NEO-STOP cassette through Cre-mediated
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Figure 5.4: Mouse breeding and B cell specific expression of
RANK(A756G). (A) Breeding scheme. For B cell specific expression of
RANK(A756G), ROSA26loxSTOPlox-RANK(A756G) mice were bred with CD19-Cre mice,
a surface protein whose expression is restricted to B cells. Cre expression leads to
the excision of the loxSTOPlox cassette, enabling transgene expression, along with
GFP. RANK(A756G) expressing B cells can thus be tracked with the aid of flow
cytometry. (B) MACS isolated B cells from CD19-Cre and RANK(A756G)CD19-Cre
mice were subjected to western blot analysis for RANK expression. (C) Cells iso-
lated from the spleens of CD19-Cre and RANK(A756G)CD19-Cre mice were analyzed
by flow cytometry for surface RANK and GFP expression. Live cells were pre-gated
for CD19 expression.
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excision of the flanking loxP sites, allows the transcription of the RANK(A756G)-
eGFP bicistronic mRNA. As a result, functionality of the generated mouse model
could be tested by flow cytometry analysis for the presence of GFP in B cells,
as well as western blot analysis. Flow cytometry analysis in spleens of 5-week old
transgenic mice showed that around 80% of the B cells are GFP positive, indicat-
ing RANK(A756G) expression. RANK(A756G) expression was also visualized by
western blot from B cells isolated from the spleen of transgenic mice and surface
expression of RANK(A756G) on B cells was demonstrated by flow cytometry analy-
sis, confirming the functionality of the generated mouse strain (Figure 5.4B). From
now on, the transgenic mice will be referred to as the RANK(A756G)CD19-Cre for
simplicity.
5.2.3 RANK(A756G)CD19-Cre mice have splenomegaly, lymph-
adenopathy and show reduced survival
RANK(A756G)CD19-Cre mice were initially observed long-term in a defined cohort
to elucidate any pathological e↵ects that B cell-specific RANK(A756G) expression
might have on mice. The mice were regularly checked for signs of disease, using
parameters such as weight and wasting, runting symptoms, lethargy or hunched
posture. A majority of the aged RANK(A756G)CD19-Cre mice showed no signs of
disease, or a significant weight change, however they died abruptly around 6 months
of age, while the CD19-Cre mice remained healthy and have survived. A detailed
necropsy of these mice showed that RANK(A756G)CD19-Cre mice had splenomegaly
and lymphadenopathy, with a 1.5 fold increase in spleen weight and significantly
elevated cell numbers in the spleen and lymph nodes (Figure 5.5A). Survival analysis
of an extended cohort of RANK(A756G)CD19-Cre mice (n=18) mice has shown that
these mice have a mean survival rate of 6.6 months (Figure 5.5B).
In order to fully understand the cause of the observed reduction in survival,
post-mortem histological analyses were performed. Organ histologies have shown
substantial cell infiltration and disrupted architecture in lymph nodes, cellular in-
filtration in the bronchioli in lungs, and the cause of death was identified as kidney
failure due to extensive glomerulonephritis (Figure 5.5C).
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Figure 5.5: RANK (K240E) expression drives disease in vivo. (A) Macro-
scopic appearance of representative spleens and mesenteric lymph nodes (in cm)
and total cell counts in spleen and lymph nodes of analyzed mice, bars indicate
mean. (B) Kaplan–Meier curve of CD19-Cre and RANK(A756G)CD19-Cre mice (n =
18, respectively)(***p  0.0001). (C) Glomerulonephritis-related kidney failure and
cellular infiltration of lungs and lymph nodes in RANK(A756G)CD19-Cre mice were
revealed by H&E staining(Scale bars: 1 mm). The data shown in A-C are obtained
from 6 month old, terminally ill animals.
5.2.4 RANK(A756G)CD19-Cre mice have immune deposits in
kidneys and accompanying proteinuria
Since the cause of death was defined as glomerulonephritis-related kidney failure,
the reason for kidney failure was investigated further in histological samples from
kidneys by immunoflourescence and scanning electron microscopy (SEM). This anal-
ysis revealed massive mesangial and subendothelial immune deposits in the kidneys
of RANK(A756G)CD19-Cre mice. The deposits were organized with regular spacing,
as is often observed in cases of lupus nephritis. This lead to the conclusion that the
extensive glomerular damage and resulting kidney failure occured due to immune
complex accumulation in the kidneys (Figure 5.6A). In line with these findings, all
of the terminally ill RANK(A756G)CD19-Cre mice (n=15) su↵ered from proteinuria,
as determined by Bradford assay, also indicating glomerular damage (Figure 5.6B).
5.2.5 RANK(A756G) expression in B cells leads to B cell
activation, proliferation and B1 B cell expansion
After observing the systemic phenotypic e↵ects of B cell-specific RANK(A756G)
expression in mice, and identifying the cause of reduced survival as kidney failure
due to immune complex deposition, the cellular responses that might lead to this
phenotype were investigated in depth. A flow cytometry analysis of the spleens of
terminally ill RANK(A756G)CD19-Cre and wildtype mice for B cell activation mark-
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Figure 5.6: RANKCD19-Cre mice succumb to deteriorating renal func-
tion. (A) SEM of kidneys in RANK(A756G)CD19-Cre mice showed massive suben-
dothelial immune deposit accumulation (representative of three mice of each geno-
type) (Scale bars: 1mm). Arrows indicate areas of interest. (B) Kidney failure in
RANK(A756G)CD19-Cre mice is also evident in significantly increased proteinuria
(n=15, respectively). The data shown in A and B are obtained from terminally ill 6
month old animals. (**p  0.01)
ers CD80 and CD86 showed that B cells in RANK(A756G)CD19-Cre mice were highly
activated. B cell size was also increased in RANK(A756G)CD19-Cre mice, indicating
activation-induced cell blasting (Figure 5.7A). CD4+ and CD8+ T cell compart-
ments, however remained una↵ected and showed no significant di↵erence in e↵ector
or memory T cell compartments (Figure 5.7B). Analysis of RANK(A756G)CD19-Cre
mice at various weeks of age, ranging from 5 to 24, showed persistent expansion in
the B1 B cell compartment, which was defined as the CD19+B220low population,
in the spleen, lymph nodes and peritoneal cavity (Figure 5.7C). Further analysis
showed a selective expansion of CD5+ B1a cells over the CD5- B1b cell population
(Figure 5.7D).
Terminally ill RANK(A756G)CD19-Cre mice showed elevated CD19+ B cell num-
bers in the lymph nodes and peritoneal cavity, whereas the B cell numbers in the
spleen remained normal, compared to the CD19-Cre mice (Figure 5.8A). An in-
tracellular Ki67 staining and flow cytometric analysis of cells from lymph nodes,
spleen and peritoneal cavity of terminally ill showed that both B1 and B2 B cells
were more proliferative in RANK(A756G)CD19-Cre mice compared to their CD19-Cre
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Figure 5.7: RANK(A756G) expression leads to B cell activation, prolif-
eration and B1a cell expansion. (A) RANK (K240E) expressing B cells show
an activated phenotype in vivo: surface CD80, CD86 expression and forward-scatter
area (FSC-A) were measured using flow cytometry. (B) Representative analysis of
T-cell populations in the spleen of terminally ill RANK (K240E)CD19-Cre mice and
6 month old CD19-Cre control animals by flow cytometry. (C) Analysis of B1 and B2
cell populations in peritoneal cavity, spleen and lymph nodes of 6 month old animals
by flow cytometry revealed B1 cell expansion. (D) B1a cell expansion in 6 month old
RANK(A756G)CD19-Cre mice revealed by flow cytometry. The cells were pre-gated
for CD19+B220low B1 population. The numbers refer to the mean percentages. The
data shown in A-D are representative of five independent experiments, with a total
number of at least 12 mice analyzed per genotype.
littermates. (Figure 5.8B). Terminally ill RANK(A756G)CD19-Cre mice also had el-
evated numbers of plasma cells (CD138+B220low) in the spleen and bone marrow
(Figure 5.8C).
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Figure 5.8: Terminally ill RANK(A756G)CD19-Cre mice have elevated
plasma cells and a highly proliferative B cell phenotype (A) Percentage
of B cells in peritoneal cavity, spleen and lymph nodes of 6 month old terminally ill
mice. (B) Ex-vivo intracellular Ki-67 staining and flow cytometry analysis of total,
B1 and B2 B cells from 6 month old mice. (C) Increased percentage of plasma cells
in the spleen and bone marrow of RANK(A756G)CD19-Cre mice. The numbers refer to
the mean percentages. The data shown in A-G are representative of five independent
experiments, with a total number of at least 12 mice analyzed per genotype.
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5.2.6 RANK(A756G) expressing B cells upregulate MHCII
and CD86 in the bone marrow
To further dissect how enforced RANK(A756G) expression a↵ects B cell pyh-
siology and development, developing B cells in the bone marrow were investigated
more closely. Incidentally, bone marrow is also a site for RANKL expression. Os-
teoblasts and bone marrow stromal cells, which are in close contact with the devel-
oping B cells express RANKL. For this purpose, B cells were isolated from the
bone marrows of RANK(A756G)CD19-Cre mice and their littermate controls and
were analyzed in detail by flow cytometry. The numbers and percentages of pro-
and pre- B cells along with immature and recirculating B cells were normal in
RANK(A756G)CD19-Cre mice. To examine whether the presence of RANKL in the
vicinity of developing RANK(A756G) expressing B cells leads to aberrant signaling,
the activation state of immature B cells in the bone marrow has been analyzed by
flow cytometry, utilizing the surface activation markers CD80, CD86 and MHCII.
Analysis of AA4.1+GFP+ immature B cells, where GFP is used as a marker for
RANK(A756G) expression, and AA4.1+GFP- immature B cells, which have not yet
expressed CD19 or RANK(A756G), revealed that GFP+ RANK(A756G) expressing
immature B cells have much higher levels of surface MHCII and CD86 compared
to GFP- immature B cells (Figure 5.9). This analysis lead to the conclusion that
RANK(A756G) expressing B cells were prematurely activated in the bone marrow.
5.2.7 RANK(A756G)CD19-Cre mice have significantly increased
anti-nuclear antibodies an immunoglobulins in serum
In light of the findings that showed premature activation of RANK(A756G) ex-
pressing immature B cells in the bone marrow, increased systemic presence of plasma
cells in terminally ill RANK(A756G)CD19-Cre mice, and immune complex deposition
in kidneys, the presence of systemic autoantibodies in RANK(A756G)CD19-Cre mice
was investigated. Sera from RANK(A756G)CD19-Cre mice and CD19-Cre mice were
collected, both at early timepoints (between weeks 9-11) and when they were termi-
nally ill. ELISA analysis was performed on the collected serum samples for several
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Figure 5.9: RANK(A756G) expressing B cells are prematurely acti-
vated in the bone marrow. (A) Representative analysis of B cell populations
within bone marrow show normal B cell development in both CD19-Cre and
RANK(A756G)CD19-Cre mice. (B) Upregulation of B cell surface activation mark-
ers CD86 and MHCII on B cells upon expression of RANK(A756G), as determined
by flow cytometry. Expression of transgene in immature B cells was traced by GFP
expression. The numbers refer to the mean percentages. The data shown are repre-
sentative of three independent experiments.
autoantibodies, such as antibodies against ssDNA, dsDNA, total ANAs and cardi-
olipin. The results demonstated significantly evelated levels of ANAs, in particular
anti-ssDNA and anti-dsDNA in RANK(A756G)CD19-Cre mice. Anti-dsDNA antibod-
ies were detected in the serum starting early in life, and their levels gradually in-
creased until the mice became terminally ill (Figure 5.10A and B). Additionally,
presence of anti-nuclear IgG and IgM class autoantibodies against cytosolic proteins
in the serum of RANK(A756G)CD19-Cre mice was visualized by HEp-2 assay, where
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the binding of serum ANAs to self antigens of a human epithelial cell line can be
visualized through indirect immunofluorescence (Figure 5.10C).
CHAPTER 5. RESULTS 57
CHAPTER 5. RESULTS 58
Figure 5.10: RANK(A756G)CD19-Cre mice have antinuclear antibod-
ies in serum. (A) Basal serum levels of total ANAs, anti-ssDNA and anti-
dsDNA in 6 month old mice. (B) Serum levels of anti-dsDNA antibodies in
RANK(A756G)CD19-Cre mice increase with age. (C) Detection of serum anti-nuclear
IgG and autoreactive IgM by immunofluorescence in RANK(A756G)CD19-Cre mice
by Hep-2 assay. (D) Basal serum levels of IgA, IgM, IgG2b and IgG3 in 3 month old
mice. (n 7 per genotype). The data are shown as the mean ± SEM.
Analysis of sera collected from RANK(A756G)CD19-Cre mice and their CD19-Cre
littermate controls by ELISA also revealed significantly elevated levels of serum IgM,
IgA, IgG2b and IgG3. (Figure 5.10D)
5.2.8 RANK(A756G)CD19-Cre mice have a polyclonal B cell
repertoire and show increased somatic hypermutation
In order to further characterize the antibody repertoire of RANK(A756G)CD19-Cre
mice, the clonality of B cells was investigated. By using a pair of primers, one of which
hybridizes to the 5’RSS sequence of all murine D segments of the IgH locus (DFS),
and the other to a region 50 bp downstream of the 4th and final J segment in the IgH
locus (JH4) in a polymerase chain reaction with genomic DNA isolated from GFP+
sorted B cells of terminally ill mice, along with CD19+ sorted B cells of littermate
controls, the clonality of the antibody repertoire was determined. As shown in Figure
5.11A, RANK(A756G)CD19-Cre mice have a polyclonal BCR repertoire, as do the
CD19-Cre mice, in line with a lymphoproliferative systemic autoimmune disease.
The rate of somatic hypermutation was determined in the RANK(A756G)CD19-Cre
mice, utilizing a set of consensus primers that hybridize to V, D or J segments of
the IgH locus in a polymerase chain reaction with genomic DNA, isolated from
B cells in the aforementioned manner. Subcloning and sequencing of the obtained
genomic fragments have revealed that the B cells from RANK(A756G)CD19-Cre carry
a significantly higher number of mutations in their V region compared to CD19-Cre
littermate controls, indicating an increased rate of somatic hypermutation (Figure
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5.11B).
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Figure 5.11: B cell repertoire of RANK(A756G)CD19-Cre mice is poly-
clonal and heavily mutated. (A) Ig clonality analysis of 6 month old mice by
PCR from genomic DNA isolated from GFP+ and CD19+ sorted B cells from
RANK(A756G)CD19-Cre and CD19-Cre mice respectively, representative of 7 mice
per genotype. Polyclonal B cells show all four possible D-JH recombinations. (B)
SHM analysis of 6 month old mice by PCR from genomic DNA isolated from GFP+
and CD19+ sorted B cells from RANK(A756G)CD19-Cre and CD19-Cre mice respec-
tively, representative of 7 mice per genotype, revealed significantly increased rate of
SHM in RANK(A756G)CD19-Cre mice. (*p  0.05)
5.3 Cellular implications of RANK(A756G) ex-
pression in B cells
5.3.1 RANK(A756G) expressing B cells are dependent on
RANKL for survival and proliferation in vitro
To determine whether the observed lymphoproliferative e↵ect of RANK(A756G)
expression on B cells is ligand dependent, total B cells were isolated from RANK
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(K240E)CD19-Cre mice and CD19-Cre mice by FACS sorting of GFP+ cells and
CD19+ cells, respectively, and stained with CellTrace Violet. CellTrace Violet is
a non-fluorescent dye that di↵uses into the cell membrane and gets cleaved by cel-
lular esterases, which converts it to a fluorescent dye. During cell division, daugther
cells receive half of the dye of the mother cell, leading to a signal reduction mea-
sured at the flow cytometer through each generation. The stained B cells were kept
in culture for 5 days in three di↵erent conditions: unstimulated; stimulated with 100
ng/µl soluble RANKL; or first stimulated with 100 ng/µl soluble RANKL, and then
treated with a neutralizing antibody ↵-RANKL 24 hours after RANKL stimulation.
Survival of cells over 5 days was measured by staining with Annexin-V, which binds
to the phosphatidylserine on the surface of apoptotic cells and 7-AAD, which binds
to dsDNA and is generally excluded from cells with an intact plasma membrane, and
flow cytometry analysis. Cell proliferation was measured by flow cytomertry anal-
ysis of the CellTrace Violet stain. An analysis of survival and proliferation showed
that RANK(A756G) expressing B cells do not survive in vitro in the absence of
RANKL. RANKL stimulated RANK(A756G) expressing B cells however, survive
and proliferate in vitro, an e↵ect that is abolished upon treatment with the neu-
tralizing antibody ↵-RANKL. CD19-Cre B cells on the other hand did not survive
in culture in response to RANKL stimulation. These results indicate that although
RANK(A756G) expression itself does not increase survival in B cells, it provides
survival and proliferative advantage upon RANKL binding (Figure 5.12).
5.3.2 Murine RANKL activates RANK(A756G) expressing
B cells in vitro
Along with the survival advantage and proliferative e↵ects of RANKL on RANK
(K240E) expressing B cells, RANK(A756G) B cells stimulated with murine RANKL
also show an activated phenotype. GFP+ sorted B cells from RANK(A756G)CD19-Cre
mice and CD19+ sorted B cells from CD19-Cre mice have been stimulated with 100
ng/µl soluble RANKL for 48 hours in culture and then analyzed for activation by
flow cytometry for the surface markers CD80, CD86 and MHCII. As shown in Figure
5.13, stimulation with RANKL leads to an activated phenotype in RANK(A756G)
CHAPTER 5. RESULTS 61
A
B
CTV
100 100 100
80 80 80
6060 60
4040 40
20 2020
0 0 0
Untreated RANKL α-RANKL
48 72 96 120 48 72 96 120 48 72 96 120
0-10 3 10 3 10 4 10 5
0
20
40
60
80
100
0-10 3 103 104 105
0
20
40
60
80
100
0-103 103 104 105
0
20
40
60
80
100
%
L
iv
e
 c
e
lls
 (
n
o
rm
a
liz
e
d
)
*
*
****
Hours in culture
RANK(K240E)
CD19-Cre
CD19-Cre
%
 o
f 
M
a
x
Hours in culture Hours in culture
CD19-Cre RANK(K240E)
CD19-Cre
Figure 5.12: RANK(A756G) expressing B cells are dependent on RANKL
for survival and proliferation in vitro. GFP+ and CD19+ sorted B cells from
2-4 month old RANK(A756G)CD19-Cre and CD19-Cre control mice, respectively, were
stained with CellTrace Violet proliferation dye and kept in culture in the presence
or absence of 100 ng/ml recombinant mouse RANKL or 2 µg purified ↵-RANKL
for 5 days. Flow cytometry analysis with Annexin-V and 7AAD stained B cells (A)
revealed enhanced survival and proliferation (B) in the presence of RANKL. The
data shown are representative of 4 independent experiments with a total of 8 mice
per genotype.
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expressing B cells, whereas it does not a↵ect the activation of CD19-Cre B cells.
Treatment with ↵-RANKL 24 hours after RANKL stimulation reduced the upreg-
ulation of the surface activation markers. Taken together, these data point to an
activated B cell phenotype with increased survival and proliferative advantage that
is dependent on the RANK-RANKL binding. Murine RANKL, which shares 85%
homology with human RANKL, was used in all the in vitro experiments, to mimick
the in vivo situation where only murine RANKL is available for the RANK(A756G)
expressing B cells. This was able to bind and activate human RANK expressed on
the murine B cells.
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Figure 5.13: murine RANKL activates RANK(A756G) expressing
B cells in vitro. GFP+ and CD19+ sorted B cells from 2-4 month old
RANK(A756G)CD19-Cre and CD19-Cre control mice respectively, were kept in culture
in the presence or absence of recombinant mouse RANKL or 2 µg purified neutral-
izing antibody ↵-RANKL for 48 hours and analyzed for activation markers CD80,
CD86, MHCII and FSC-A by flow cytometry (n=6)
5.3.3 In vitro and in vivo activated T cells express RANKL
Since RANK(A756G) expressing B cells are dependent on RANKL for survival and
proliferation, the possible cell-cell interactions which would enable the RANK(A756G)
expressing B cells in RANK(A756G)CD19-Cre mice to bind RANKL were investigated
next. Previous studies have shown that bone marrow stromal cells, which are in
close contact with the B cells during their development in the bone marrow ex-
press RANKL, as well as activated T cells which contact B cells in the periphery.
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Figure 5.14: Activated CD4+T cells express RANKL in vivo. (A) MACS
purified CD4+ T cells from the spleens of RANK(A756G)CD19-Cre mice were analyzed
by flow cytometry for surface RANKL expression. (B) Kinetics of RANKL surface
expression on MACS purified and CD3/CD28 activated CD4+T cells, as determined
by flow cytometry analysis and represented as mean fluorescence intensity. Surface
RANKL expression peaks 48 hours after stimulation. The data are representative of
at least two independent experiments.
As Figure 5.14A shows, e↵ector CD4+ T cells from the spleen and lymph nodes
of RANK(A756G)CD19-Cre and CD19-Cre mice, which are gated as the CD44high,
CD62Llow cells in flow cytometry analysis, have upregulated surface RANKL expres-
sion, compared to the naive CD4+ T cell compartment which is CD62LhighCD44low.
In order to determine the kinetics of the upregulation of surface RANKL expression
upon activation on T cells, CD4+ T cells were magnetically isolated (MACS) from
spleens and lymph nodes of RANK(A756G)CD19-Cre and CD19-Cre mice, activated
in vitro by CD3/CD28 ligation and checked for upregulation of surface RANKL by
flow cytometry. Figure 5.14B shows surface RANKL expression starts to increase
as early as 1 hour after activation, and reaches its peak at 48 hours, before de-
clining at 72 hours. Similar results were observed for both RANK(A756G)CD19-Cre
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and CD19-Cre control mice (data not shown). Taken together these data show that
activated CD4+ T cells express surface RANKL in a time-dependent manner and
are a potential source of RANKL for RANK(A756G) expressing B cells during their
interaction in the secondary lymphoid tissues such as the spleen or lymph nodes.
5.3.4 In vitro activated T cells induce a more activated phe-
notype in RANK(A756G) expressing B cells than in
wildtype B cells
After confirming and establishing the kinetics of surface RANKL expression in in
vivo and in vitro activated T cells, respectively, the e↵ect of the interaction be-
tween RANK(A756G) expressing B cells and RANKL expressing T cells were in-
vestigated next. CD4+ T cells isolated via negative magnetic labelling (MACS),
from the spleens and lymph nodes of RANK(A756G)CD19-Cre mice were activated in
vitro with CD3/CD28 for 48 hours, the time point when the surface expression of
RANKL peaks. RANK(A756G) expressing B cells isolated by sorting for GFP, and
CD19-Cre B cells isolated by sorting for CD19+ cells were added on the activated
CD4+ T cells at this time point. Activation status of the B cells was measured 24
hours later using flow cytometry analysis for the surface activation markers CD80,
CD86 and MHCII. This analysis has revealed that RANK(A756G) expressing B cells
have a more activated phenotype after interacting with activated T cells compared
to the CD19-Cre B cells, indicated by a higher CD80 and CD86 surface expression,
as well as an increased forward-scatter due to larger cell size. Therefore, the RANK-
RANKL interaction among B and T cells is non-redundant and provides a marked
increase in B cell activation. The data therefore demonstrated that RANKL bind-
ing with RANK provides the RANK(A756G) expressing B cells with an additional
activating signal, and leads to a highly activated B cell population that would have
survival and proliferative advantage in the periphery upon contact with CD4+ T
cells (Figure 5.15A).
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Figure 5.15: RANK(A756G) expressing B cells are highly activated
by CD4+ T cells. GFP+ and CD19+ sorted B cells from 2-4 month old
RANK(A756G)CD19-Cre and CD19-Cre control mice, respectively, were incubated
with MACS isolated, CD3/CD28 activated CD4+ T cells for 48 hours and analyzed
for B cell surface activation markers by flow cytometry. The data shown are repre-
sentative of 3 independent experiments with at least 6 mice per genotype. (C) IHC
staining of bone marrows from 2-4 month old RANK (K240E)CD19-Cre mice show
CD20+ B cells in the vicinity of RANKL+ bone marrow stromal cells (Scale bars:
1mm).
5.3.5 ST2, a bone marrow stromal cell line, induces a more
activated phenotype and an increased proliferative ca-
pacity in RANK(A756G) expressing B cells
As another potential resource of RANKL for RANK(A756G) expressing B cells,
bone marrow stroma has an essential role in the development and di↵erentiation of
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B cells. As was explained in Section 5.2.6, immature RANK(A756G) expressing B
cells upregulate MHCII and CD86 on their surface, indicating a prematurely acti-
vated phenotype. To further elucidate the e↵ect of RANKL expression by stromal
cells on RANK(A756G) expressing B cells, a RANKL expressing stromal cell line,
ST2 was used in co-culture experiments. GFP+ sorted RANK(A756G) expressing
B cells from spleens of RANK(A756G)CD19-Cre mice and CD19+ sorted B cells from
CD19-Cre mice were stained with CellTrace Violet and cocultured with pre-plated
ST2 cells for 96 hours, and checked for surface activation markers as well as pro-
liferation by flow cytometry. Figure 5.15B shows that RANK(A756G) expressing B
cells proliferate more than CD19-Cre B cells in the presence of ST2 cells. ST2 cells
also induce a more activated phenotype in RANK(A756G) expressing B cells, indi-
cated by a higher expression of surface CD80, CD86, MHCII and also an increase
in cellular size. Taken together, these data indicate that RANK(A756G) expressing
B cells are highly activated and proliferate more in vitro in the presence of RANKL
expressing ST2 cells, supporting the observation of the presence of prematurely ac-
tivated immature B cells in the bone marrow of RANK(A756G)CD19-Cre mice. In
addition, immunohistochemistry (IHC) staining for RANKL and CD20 in serial sec-
tions from the bone marrows of RANK(A756G)CD19-Cre mice showed CD20+ B cells
in the vicinity of RANKL expressing cells, as expected, where they interact with the
bone marrow stroma during their development (Figure 5.15C).
5.3.6 RANK(A756G) expressing B cells show activation of
PI3K and MAPK pathways upon RANKL stimulation
To elucidate which signaling pathways are involved in RANK(A756G) mediated
B cell leads to enhanced survival, proliferation and activation, RANK(A756G) ex-
pressing B cells from the spleens of RANK(A756G)CD19-Cre mice have been sorted
for GFP+ and stimulated with 100 ng/ul RANKL or 0.5 µ CpG for 48 hours in cul-
ture, along with CD19+ sorted CD19-Cre B cells. Total cell lysates were obtained
following stimulation and immunoblotted for phosphorylation in proteins that are
known to be downstream of RANK. While components of both the canonical and
the non-canonical NF-B pathway showed no di↵erence in phosphorylation upon
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RANKL stimulation (data not shown), Akt and ERK and JNK family MAP kinases
have shown remarkably increased phosphorylation in response to RANKL stimula-
tion, and in lower levels in response to CpG stimulation. CD19-Cre B cells on the
other hand, did not respond to RANKL stimulation, as no di↵erence in phosphory-
lation levels of Akt or MAPKs was observed and these cells were only responsive to
CpG stimulation, showing that RANK(A756G) expressing B cells achieve survival
and proliferative advantages due to an upregulation in PI3K and MAPK signaling
upon RANKL binding, and not in steady state (Figure 5.16A). In addition, the
pharmacological inhibition of the JNK and PI3K pathways lead to reduced survival
of transgenic B cells, when administered 24 hours after stimulation with RANKL,
further indicating that RANK(A756G) expression leads to the survival of transgenic
B cells through the activation of MAPK and PI3K pathways upon RANKL stimu-
lation (Figure 5.16B).
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Figure 5.16: RANK(A756G) expressing B cells upregulate MAPK and
PI3K signaling upon RANKL stimulation. (A) GFP+ and CD19+ sorted B
cells from 4 month old RANK(A756G)CD19-Cre and CD19-Cre control mice, respec-
tively, were stimulated with 100 ng/ml recombinant mouse RANKL or 0.5 µM CpG
for 48 hours, and subsequently subjected to western blotting. (B) Pharmacological
inhibition of JNK pathway with SP600125 and PI3K pathway with Cal-101 24 hours
after stimulation with RANKL abolishes the survival benefit of RANK(A756G) ex-
pressing B cells. The data shown are representative of at least two independent
experiments.
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5.3.7 RANK(A756G) expressing B cells di↵erentially ex-
press genes related to survival, proliferation and sig-
naling
As previously explained, RANK(A756G) expression in B cells drives survival, prolif-
eration and activation. After establishing that RANK signaling leads to such e↵ects
through the activation of MAPK and PI3K pathways, the di↵erential expression
of genes important in cell survival and proliferation in RANK(A756G) B cells was
investigated. For this purpose, RT-PCR analysis was performed on cDNA isolated
from GFP+ and CD19+ sorted and pooled B cells from the spleen, lymph nodes and
peritoneal cavity of 20-week-old RANK(A756G)CD19-Cre sorted B cells from CD19-
Cre mice, respectively. The target genes were chosen based on microarray analysis
and their relevance in cell survival and proliferation (data not shown). Di↵erences
in gene expression patterns demonstrated by the microarray data were reproduced
for several genes by RT-PCR. Among them were the apoptosis related genes such as
Bcl-2, APC and PTEN; from which Bcl2 is an anti-apoptotic and APC and PTEN
are pro-apoptotic genes. As expected, Bcl-2 was upregulated, whereas APC and
PTEN were downregulated in RANK(A756G) expressing B cells. CyclinD1, which is
a positive regulator of cellular proliferation has been upregulated in RANK(A756G)
expressing B cells; as are Malt1 and IKK , which are positive regulators of the NF-
B pathway (Figure 5.17). Taken together these data indicate that RANK(A756G)
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Figure 5.17: RANK(A756G) expressing B cells upregulate prosurvival
and antiapoptotic genes in vivo. Transcript levels of cyclinD1, Bcl-2, APC,
PTEN, IKKB and MALT-1 in GFP+ and CD19+ sorted B cells from 20 week
old RANK(A756G)CD19-Cre and CD19-Cre control mice, respectively. Normalized to
Actin; n   7 per genotype.
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expression in B cells leads to the upregulation of genes that are positive regulators
of survival and proliferation and downregulation of genes that promote apoptosis,
an e↵ect that is mediated through the upregulation of MAPK and PI3K signaling
upon ligand binding.
Chapter 6
Discussion
Receptor activator of NF-B is an important receptor standing in the cross-
roads of several pathways which regulate cellular growth and replication. Given its
influence on both bone homeostasis and development of several components of the
immune system and its essential role in “osteoimmunology”, the aim of the present
study was to elucidate the e↵ects of deregulated RANK signaling in B cells in vivo.
To tackle this question, B cell restricted enforced expression of the RANK(A756G)
mutation, which was described for 8% of ABC-DLBCL patients, was the selected
approach. Analysis of this genetic mouse model revealed that deregulated RANK
signaling in the pre-B cell stage is su cient to drive lymphoproliferation and au-
toimmunity in vivo, with SLE-like manifestations such as glomerulonephritis and
the presence of ANAs in the serum. Initial experiments in vitro in Bal17 cells were
performed to gain a fundamental understanding of the consequences of enforced
RANK expression in B cells. These showed that the RANK(A756G) mutant ex-
pression leads to a marginal increase in B cell activation in response to RANKL
stimulation, compared to the wildtype RANK expressed at equal amounts. Ex vivo
experiments with transgenic RANK(A756G) expressing B cells also showed that
in the absence of the ligand stimulation, RANK(A756G) expression in transgenic B
cells provides marginal survival advantage over wild type B cells. On the other hand,
ex vivo experiments also showed that lymphoproliferative e↵ects of RANK(A756G)
were mainly ligand dependent. Therefore, the overexpression of this receptor on the
surface of B cells is largely responsible for the survival benefit of the transgenic B
70
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cells. Hence, it can be concluded that the enforced RANK(A756G) expression leads
to enhanced survival and proliferation of transgenic B cells due to a synergistic e↵ect
between RANK overexpression and the K240E mutation.
Based on the literature and the observations in Bal-17 cells in this study, the pos-
tulated hypothesis was that enforced RANK(K240) expression in B cells would drive
pathology. The disease induced by B cell specific enforced RANK(A756G) expression
manifested itself through a shortened lifespan, enlarged secondary lymphoid organs
and glomerulonephritis-related kidney failure. Deterioration of renal function was
also clearly reflected in the development of proteinuria in RANK (K240E)CD19-Cre
mice. A closer look at the kidneys revealed massive accumulation of immune com-
plexes, reminiscent of lupus nephritis [110]. Kidney disease is a very common com-
plication in systemic autoimmune diseases and 90% of systemic lupus erythematous
(SLE) patients su↵er from some form of kidney disease [111]. The B cell phenotype in
RANK(A756G)CD19-Cre mice was highly activated and proliferative, and showed an
expansion of the B1 B cell compartment, with an emphasis on the B1a B cells, a trait
which was described for several mouse models of lupus [112]. The most solid indica-
tion of an autoimmune disease in these mice was provided by the presence of ANAs
in the serum. ANAs, and especially anti-dsDNA presence is a very strong indicative
of SLE in humans and mouse models [113]. An increase in serum immunoglobulins,
mostly in IgM, IgG2b, IgA and IgG3 was also observed. It was demonstrated in
several mouse models of lupus that B2 B cells preferentially class switch to IgA and
IgG2b during disease [114]; whereas IgM is the immunoglobulin spontaneously se-
creted by B1 B cells [115]. An increase in plasma cells in the spleen and bone marrow
in transgenic mice was also observed. In line with this finding, an elevation of plasma
cells in the circulating blood and tonsils during disease flares in SLE patients, along
with increased numbers of plasma cells in the bone marrow in SLE mouse models
were previously reported [116, 117]. The B cell repertoire of the transgenic mice was
polyclonal and showed increased rates of somatic hypermutation, which was also de-
scribed in SLE mouse models [118]. Taken together, the data obtained showed that
enforced RANK(A756G) expression on B cells during early stages of development
in the bone marrow drives an autoimmune disease characterized by B cell activation
and proliferation, renal failure and presence of ANAs.
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We observed that enforced RANK(A756G) expression leads to the activation
and enhanced survival and proliferation of transgenic B cells upon RANKL binding
through the MAPK and PI3K signaling pathways, and that inhibiting the JNK and
PI3K pathways leads to a drastic drop in transgenic cell survival. Transgenic B cells
that start expressing RANK(A756G) during the pre-B cell stage in the bone marrow.
These already have access to the RANKL secreted by the bone marrow stromal cells,
which might provide them with an initial activating “hit” and a survival advantage
through the immune checkpoints in the bone marrow aimed to eliminate autoreac-
tive cells by activating these signaling pathways. Indeed, a closer look into the bone
marrow of RANK(A756G)CD19-Cre mice revealed that upon RANK(A756G) expres-
sion, immature transgenic B cells had a marked increase in the surface expression
of MHCII and CD86. Immature B cells developing in the bone marrow of Bl6 mice
are unable to upregulate MHCII and CD86 upon antigen binding, a phenomenon
that is thought to prevent premature activation of a B cell, and thus autoimmunity
[119]. A prematurely activated B cell phenotype in the bone marrow, as is observed
in RANK(A756G)CD19-Cre, might lead to the escape of many autoreactive B cells
from the central tolerance checkpoint to the periphery, resulting in the autoimmune
phenotype that is observed in mice.
Considering the many similarities between autoimmunity and lymphoma, it is
not surprising that the expression of a somatic mutation that is observed in DLBCL
patients leads to autoimmunity in mice, although it might initially seem unantic-
ipated. SLE is associated with a 2.7 fold increase in NHL risk overall [120]. Both
diseases require the breakdown of checkpoints that control lymphocyte proliferation,
both contain somatic and inherited mutations in several important components of
pathways that regulate apoptosis and cell proliferation, such as the Fas mutation
that is common to both lymphomas and autoimmune diseases [121]. In addition,
both diseases can be triggered by Epstein-Bar virus infections, show dysregulation
of the cytokines IL-4, IL-6, IL-8 and IL-10 and overexpression of the B-cell acti-
vating factor (BAFF) is found in SLE and rheumatoid arthritis, as well as NHL
[122, 123, 124, 125, 126].
Importantly, we have observed that the phenotype in RANK(A756G) CD19-Cre
mice was ligand dependent and that the RANKL provided the transgenic B cells with
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a survival and proliferative advantage. Ex vivo experiments with RANK(A756G) ex-
pressing B cells showed that murine RANKL stimulation was required to activate
transgenic B cells and enhanced the survival and proliferative abilities of the trans-
genic B cells. This e↵ect was partially abrogated by administration of neutralizing
↵-RANKL antibody on the stimulated cells. Neutralizing antibody had no e↵ect in
the absence of RANKL.
After establishing that transgenic B cells require RANKL for survival and prolif-
eration, an important question to answer was to identify the source of RANKL, and
how the interaction of transgenic B cells with the RANKL expressing cells would
a↵ect the physiology of the B cell. Several cell types express either membrane-bound
or soluble RANKL, of which two are most important for B cell development and
a response against pathogens. One is the osteoblasts, which are part of the bone
marrow stroma where B cells develop, and the other is the CD4+ T cells, which
interact with B cells in the periphery during antigen response, and express RANKL
upon activation. To test whether B cell interaction with these two cell types would
lead to any changes in B cell activation or proliferation, co-culture experiments were
performed. Indeed, upon co-culturing with in vitro activated CD4+ T cells, the
transgenic B cells showed higher activation compared to wild type B cells. Similarly,
transgenic B cells co-cultured with a bone marrow stromal cell line ST2, were more
activated and proliferated more compared to wild type B cells. These findings led to
the conclusion that RANKL expression by bone marrow stromal cells and activated
CD4+T cells provided the transgenic B cells with an additional activating signal,
leading to a proliferative advantage for RANK(A756G) expressing B cells.
TNF family receptors and ligands have long been implicated in inflammatory
and autoimmune diseases. Elevated TNF levels have been observed in autoimmune
diseases such as rheumatoid arthritis and inflammatory bowel disease [127]. Dereg-
ulation of and mutations in Fas/FasL signaling axis, also members of the TNF
superfamily, have been implicated in mice models of SLE, as well as in SLE pa-
tients [128]. High levels of BAFF, also a TNF superfamily member, in the serum
of SLE patients is also associated with increased autoantibody presence and beli-
mumab, a monoclonal antibody that inhibits BAFF is approved by the FDA for
SLE treatment [129, 130]. TNF blockade alleviates antigen-induced arthritis in rats.
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Inhibition of TL1A/DR3, another TNF/TNFR superfamily member is indicated as
a potential therapeutic approach for several autoimmune diseases such as inflam-
matory bowel disease and rheumatoid arthritis [131]. Mice lacking RANKL in T
cells were protected from experimental autoimmune encephalomyelitis (EAE), and
pharmacological RANKL inhibition also prevented the development of EAE [132].
Similarly to autoimmune diseases, deregulation of RANK-RANKL signaling axis
is also implicated in several types of lymphoid malignancies. RANK and RANKL
expression is detected on Hodgkin’s lymphoma cell lines, enabling an autocrine pos-
itive feedback loop that enhances cell survival and proliferation. B-CLL cells also
overexpress RANK, which leads to an evasion of apoptosis through IL-8. RANKL
expressed by multiple myeloma cells also induce a proliferation of the cells of myeloid
lineage in the bone marrow through IL-6, enhancing the access of malignant cells to
the proliferation inducing ligand (APRIL) produced by the myeloid cells (63). The
RANK(A756G) mutation is observed in 8% of a cohort of ABC-DLBCL patients.
Taking all this data into consideration, the following model of disease devel-
opment for RANK(A756G)CD19-Cre mice is proposed. B cells start expressing the
transgene RANK(A756G) during the pre-B cell stage bind RANKL that is expressed
on the bone marrow stroma. This leads to a prematurely activated cell phenotype
with survival advantages through upregulation of MAPK and and PI3K pathways.
Thereby central checkpoints are circumvented, even if they are autoreactive. These
proliferative autoreactive cells in turn, move to the periphery where they encounter
their nuclear antigens (as a result of cell death, for instance). CD4+T cells that have
upregulated surface RANKL which might enhance their proliferative and survival
abilities, leading to excessive production of autoantibodies and immunoglobulins,
which in turn accumulate in the kidneys, resulting in defects in renal function and
lead to death through severe kidney failure. The novel mouse model described here
reveals that RANK(A756G) overexpression drives disease in vivo by enhancing B cell
survival and proliferation; provides insight into the role of RANK signaling in B cells,
outside the context of bone-related disorders and sheds new light on a possible target
receptor in B-cell related malignancies, where RANK signaling is known to be dereg-
ulated. These include several lymphoid malignancies, such as Hodgkin’s lymphoma,
CLL and multiple myeloma, as well as autoimmune disorders. Based on the find-
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ing of ligand-dependent signaling of RANK(A756G), RANKL inhibitors might be
functional in RANK(A756G)-mutated ABC-DLBCL. Furthermore, it was observed
that the JNK and PI3K pathways are crucial for mediating RANK(A756G) induced
proliferation. Based on the success of the PI3K inhibitor CAL-101 in clinical trials,
this might also be useful for RANK-mutated ABC-DLBCL [133]. RANK-RANKL
signaling axis is already being targeted for treatment of skeleton-related diseases and
the RANKL inhibitor Denosumab was approved by the FDA for osteoperosis and
skeleton-related events following malignancies such as bone metastases and giant
cell tumor of bone. The study at hand indicates that RANKL inhibitors could also
be used for the treatment of B cell malignancies, possibly in combination with other
therapies.
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5.1 Schematic depiction of RANK(A756G) mutation. Red arrow
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5.4 Mouse breeding and B cell specific expression of RANK(A756G).
(A) Breeding scheme. For B cell specific expression of RANK(A756G),
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scopic appearance of representative spleens and mesenteric lymph
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analyzed mice, bars indicate mean. (B) Kaplan–Meier curve of CD19-
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0.0001). (C) Glomerulonephritis-related kidney failure and cellular
infiltration of lungs and lymph nodes in RANK(A756G)CD19-Cre mice
were revealed by H&E staining(Scale bars: 1 mm). The data shown
in A-C are obtained from 6 month old, terminally ill animals. . . . . 49
5.6 RANKCD19-Cre mice succumb to deteriorating renal function.
(A) SEM of kidneys in RANK(A756G)CD19-Cre mice showed massive
subendothelial immune deposit accumulation (representative of three
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5.7 RANK(A756G) expression leads to B cell activation, prolif-
eration and B1a cell expansion. (A) RANK (K240E) expressing
B cells show an activated phenotype in vivo: surface CD80, CD86 ex-
pression and forward-scatter area (FSC-A) were measured using flow
cytometry. (B) Representative analysis of T-cell populations in the
spleen of terminally ill RANK (K240E)CD19-Cre mice and 6 month
old CD19-Cre control animals by flow cytometry. (C) Analysis of B1
and B2 cell populations in peritoneal cavity, spleen and lymph nodes
of 6 month old animals by flow cytometry revealed B1 cell expansion.
(D) B1a cell expansion in 6 month old RANK(A756G)CD19-Cre mice re-
vealed by flow cytometry. The cells were pre-gated for CD19+B220low
B1 population. The numbers refer to the mean percentages. The data
shown in A-D are representative of five independent experiments, with
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5.8 Terminally ill RANK(A756G)CD19-Cre mice have elevated plasma
cells and a highly proliferative B cell phenotype (A) Percent-
age of B cells in peritoneal cavity, spleen and lymph nodes of 6 month
old terminally ill mice. (B) Ex-vivo intracellular Ki-67 staining and
flow cytometry analysis of total, B1 and B2 B cells from 6 month
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bone marrow of RANK(A756G)CD19-Cre mice. The numbers refer to
the mean percentages. The data shown in A-G are representative of
five independent experiments, with a total number of at least 12 mice
analyzed per genotype. . . . . . . . . . . . . . . . . . . . . . . . . . . 53
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5.9 RANK(A756G) expressing B cells are prematurely activated
in the bone marrow. (A) Representative analysis of B cell popu-
lations within bone marrow show normal B cell development in both
CD19-Cre and RANK(A756G)CD19-Cre mice. (B) Upregulation of B
cell surface activation markers CD86 and MHCII on B cells upon
expression of RANK(A756G), as determined by flow cytometry. Ex-
pression of transgene in immature B cells was traced by GFP expres-
sion. The numbers refer to the mean percentages. The data shown
are representative of three independent experiments. . . . . . . . . . . 55
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serum. (A) Basal serum levels of total ANAs, anti-ssDNA and anti-
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ies in RANK(A756G)CD19-Cre mice increase with age. (C) Detection of
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clonal and heavily mutated. (A) Ig clonality analysis of 6 month
old mice by PCR from genomic DNA isolated from GFP+ and CD19+
sorted B cells from RANK(A756G)CD19-Cre and CD19-Cre mice re-
spectively, representative of 7 mice per genotype. Polyclonal B cells
show all four possible D-JH recombinations. (B) SHM analysis of 6
month old mice by PCR from genomic DNA isolated from GFP+
and CD19+ sorted B cells from RANK(A756G)CD19-Cre and CD19-
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significantly increased rate of SHM in RANK(A756G)CD19-Cre mice.
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5.12 RANK(A756G) expressing B cells are dependent on RANKL
for survival and proliferation in vitro. GFP+ and CD19+ sorted
B cells from 2-4 month old RANK(A756G)CD19-Cre and CD19-Cre
control mice, respectively, were stained with CellTrace Violet prolif-
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purified CD4+ T cells from the spleens of RANK(A756G)CD19-Cre
mice were analyzed by flow cytometry for surface RANKL expres-
sion. (B) Kinetics of RANKL surface expression on MACS purified
and CD3/CD28 activated CD4+T cells, as determined by flow cytom-
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CD4+ T cells. GFP+ and CD19+ sorted B cells from 2-4 month
old RANK(A756G)CD19-Cre and CD19-Cre control mice, respectively,
were incubated with MACS isolated, CD3/CD28 activated CD4+ T
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